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ABSTRACT 
 
 
PREDICTORS OF LATE STAGE CERVICAL CANCER DIAGNOSES AND DISPARITIES IN THE U.S. 
 
(A CLOSER LOOK AT THE INTERACTIONS BETWEEN CHARACTERISTICS OF ACCESS, WOMEN & 
PLACE) 
 
 
By 
 
YAMISHA S. RUTHERFORD 
 
 
AUGUST 29, 2019 
 
 
Background: Approximately 51% of women with cervical cancer (CVC) are diagnosed at a late 
stage (regional or distant), an outcome associated with increased morbidity and mortality.
 
African American, and Hispanic women,
 
and women residing in specific geographic regions of 
the (US) are among those most heavily burdened by late stage CVC.
 
The cause(s) of these 
disparities are multifaceted and not well understood. However, the most significant predictor of 
late stage CVC diagnosis and disparities is current screening, which is largely impacted by 
access to care. Thus, the goal of this study was to identify access-related predictors of late stage 
CVC and develop a comprehensive understanding of where and why racial and geographic 
disparities in late stage CVC occur. Methods: This three-part study examined primary CVC 
cases diagnosed between the years of 2005-2014, from the United States Cancer Statistics 
(USCS) database. The final sample included 120,325 CVC cases within 43 states and their 
2,357constituent counties. First, Empirical Bayes LISA clustering methods were applied to 
identify clusters of counties considered to be high risk for late stage CVC “hotspots” during two 
5-year time periods (pre- and post-2010). Second, a series of T-tests were conducted to 
determine whether various contextual and compositional factors were significantly different in 
hotspots versus other places. Third, two Generalized Linear Mixed Models (GzLMM), using 
data from person and county levels, were estimated to identify predictors of late stage CVC 
diagnosis and racial or ethnic disparities among women with CVC in the US. Lastly, a General 
Linear Mixed Model (GLMM) using data from county- and state –levels was estimated to 
ii 
 
examine predictors of higher proportions of late stage CVC among counties. Results: Primary 
care physician shortage areas, Planned Parenthood (PPH) clinics, area-level poverty rates, area-
level uninsured rates, percent of immigrants from other countries, state CVC screening mandates 
and prevalence of self-insured employer health plans were all statistically significant predictors 
of access to care associated with late stage CVC diagnoses and geographic disparities. We also 
found that PPH clinics play an important role in reducing the odds of late stage CVC among 
Hispanic women with CVC. Conclusion: Access to CVC screening plays a significant role in 
the etiological pathway to late stage CVC diagnoses and disparities. Given that significant access 
barriers occurred at various ecological and geographical levels, it is recommend that future 
research and intervention efforts begin to focus on multilevel and/or spatial approaches. Without 
further exploration of the factors impacting late stage CVC diagnoses, CVC mortality rates will 
remain high and at a disproportionately higher rate for women in various geographical areas and 
among African American and Hispanic women. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
PREDICTORS OF LATE STAGE CERVICAL CANCER DIAGNOSES AND DISPARITIES IN THE U.S. 
 
(A CLOSER LOOK AT THE INTERACTIONS BETWEEN CHARACTERISTICS OF ACCESS, WOMEN & 
PLACE) 
 
 
 
 
by 
 
YAMISHA S. RUTHERFORD 
 
 
 
 
B.S., SPELMAN COLLEGE 
 
M.P.H., MOREHOUSE SCHOOL OF MEDICINE 
 
 
 
 
 
 
 
 
 
 
A Dissertation Submitted to the Graduate Faculty 
of Georgia State University in Partial Fulfillment 
of the 
Requirements for the Degree 
 
 
 
DOCTOR OF PHILOSOPHY IN PUBLIC HEALTH 
 
 
 
 
ATLANTA, GEORGIA 
30303 
 
 
iv 
 
APPROVAL PAGE 
 
 
PREDICTORS OF LATE STAGE CERVICAL CANCER DIAGNOSES AND DISPARITIES IN THE U.S. 
 
(A CLOSER LOOK AT THE INTERACTIONS BETWEEN CHARACTERISTICS OF ACCESS, WOMEN & 
PLACE) 
 
 
by  
 
 
 YAMISHA S. RUTHERFORD 
 
 
 
 
 
 
Approved:  
 
 
 
_________________________________ 
Lee Rivers Mobley, Ph.D.  
Committee Chair  
 
 
 
_________________________________ 
May Kuo, Ph.D. 
Committee Member  
 
 
 
_________________________________ 
Harry J. Heiman, M.D. 
Committee Member  
 
 
 
 
Dissertation Defense Date  
AUGUST 29, 2019 
v 
 
Acknowledgments 
 
I would like to thank both the National Cancer Institute and the Centers for Disease Control and 
Prevention. This study was funded by a National Cancer Institute grant (2R01CA126858). 
However, Centers for Disease Control and Prevention’s National Program of Cancer Registries 
also contributed funds to cover the standard RDC fees for researchers conducting analyses under 
approved research projects. The content is solely the responsibility of the authors and does not 
necessarily represent the official views of Georgia State University, the University of North 
Carolina, the National Center for Health Statistics, the National Cancer Institute, or the National 
Institutes of Health. 
 
I would also like to thank my dissertation chair and committee members: Lee Mobley, PhD, 
Harry Heiman, MD and May Kuo, PhD. This research would not be possible without the data, 
instruction, and teachings provided by my dissertation chair, Dr. Lee Mobley. Dr. Mobley has 
helped to mode me into a better scientific researcher and I am grateful for her mentorship over 
the past three years. I am also grateful for my committee members who provided me with 
additional guidance and support.  
 
Finally, I would like to thank God and my family for providing me with peace and balance 
during my dissertation process. I’m grateful for the many ways that they encouraged me and 
helped me to relieve stress. May they continue to be beacons of light for myself and others.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
Author’s Statement Page 
 
 
August 29, 2019 
 
 
In presenting this dissertation as a partial fulfillment of the requirements for an advanced 
degree from Georgia State University, I agree that the Library of the University shall make it 
available for inspection and circulation in accordance with its regulations governing materials of 
this type. I agree that permission to quote from, to copy from, or to publish this dissertation may 
be granted by the author or, in his/her absence, by the professor under whose direction it was 
written, or in his/her absence, by the Associate Dean, School of Public Health. Such quoting, 
copying, or publishing must be solely for scholarly purposes and will not involve potential 
financial gain. It is understood that any copying from or publication of this dissertation which 
involves potential financial gain will not be allowed without written permission of the author.  
 
 
 
              ___________________________________ 
              Yamisha S. Rutherford 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
Table of Contents 
Chapter One……………………………………………………………………………...............1 
Introduction………………………………………………………………………….........1 
Literature Review………………………………………………………………………....2 
Cervical Cancer Epidemiology & Prevention………………………………..…...2  
Late Stage Cervical Cancer & Disparities…………………………………...……3  
Factors Impacting Late Stage Cervical Cancer…………………………………...4 
The Role of Access in CVC Screening…………………………………………...5 
The Affordable Care Act & Access to CVC Screening…………….…………….7 
Problem Statement: Limitations in Literature……………………………………………8 
Unexplored Constructs of the Access Framework……………………………….9 
Primary Care Physician Shortages & Underserved Populations….……10  
Nurse Practitioner Regulations……………………………………….….10 
Community Health Centers & Publicly-Funded Clinics……………….11 
State CVC Screening Insurance Mandates& Self Insured Plans…..…….12 
Multilevel Modeling……………………………………………………………..14  
Spatial Analytic Methods & Perspective………….……………………………..16
 
Summary of Limitations…………..……………………………………………..17 
Statement of Purpose & Research Aims…………..……………………………………..17 
Specific Aim 1…………..……………………………………………………….18 
Specific Aim 2…………..……………………………………………………….20 
Specific Aim 3…………..……………………………………………………….20 
   Significance…….…………….…..…………………………………………………….22 
References…………..………………………………………………………....................24 
Chapter Two: Examining Spatial Clusters of High & Low Proportions of Late Stage 
Cervical Cancer in the U.S.: A Look at Geographic Disparities & Associated Risk 
Factors...........................................................................................................................................36 
Introduction………...……….…..………………………………………………………..36 
Methods……….…...……….…..………….……………………………………………..38 
Study Population……….…..........……………………………………………….38 
Statistical Analysis..…….…..........…………………………………………….39 
Results………….…...……….…..……………………………………………………..42 
LISA Cluster and Persistent Hotspot Results………………………...………….42 
Comparison of High and Low Rate Clusters: T-test Results….…………………43 
Discussion……….…...……….…..……………………………………………...………44 
References……….…...……….…..…………………………………………………48 
Figures and Tables.…...……….…..…………………………………………………52 
Chapter Three: Availability and Affordability of Care Influencing Late Stage Cervical 
Cancer Diagnoses and Disparities in the U.S.   …………………………….……………...…58 
Introduction………...……….…..………………………………………………………..58 
Availability – Primary Care Physician Shortage………………………………...59 
viii 
 
Affordability- Community Health Centers & Publicly-Funded Clinics…………60 
Methods……….…...……….…..………………………………………………………..61 
Conceptual Model…………………………………………………….………….61 
Study Population……….…..........……………………………………………….64 
Measures……….…..........……………………………………………………….65 
Statistical Analysis..…….…..........……………………………………………....66 
Results………….…...……….…..……………………………………………………….67 
Descriptive Statistics………………….………………………………………….67 
Multilevel Model Results………………………………………………….……..68 
Discussion……….…...……….…..……………………………………………………71 
References……….…...……….…..…………………………………………………77 
Figures and Tables.…...……….…..…………………………………………………84 
Chapter Four: Multilevel Access Barriers Influencing Geographic Disparities in Late Stage 
Cervical Cancer among Counties in the U.S.. …………………………………………...…92 
Introduction………...……….…..……………………………………………………….92 
Nurse Practitioner Regulations………………..………………………………....94 
Cervical Cancer Screening Mandates & Self-Insured Plans……………..………95 
Conceptual Model…………………………………………………….………….97 
Methods……….…...……….…..……………………………………………………….100 
Study Population……….…......................……………………………………100 
Outcome Variable….........……………………………………………………101 
County-level Explanatory Variables….........……………….………………...101 
State-level Explanatory Variables….........………………....…………………103 
Statistical Analysis..…….…..........……………………………...……………104 
Results………….…...……….…..……………………………………………………105 
Descriptive Statistics………………….………………………………………105 
Multilevel Model Results………………………………………………….……106 
Discussion……….…...……….…..…………………………………………………….107 
References……….…...……….…..………………………………………………112 
Figures and Tables.…...……….…..……………………………………………120 
Chapter Five……………………………………………………………………………...........125 
Summary of Background, Gaps in Literature & Specific Aims…………………..........125 
Summary of Results & Implications…...........................................................................126 
Summary of Study 1 Results & Implications…………………………..............126 
Summary of Study 2 Results & Implications…...............…................…...........127 
Summary of Study 3 Results & Implications…...............…................…...........128 
Study Limitations…..…………………………………………………………………130 
Future Research………………………………………………………………………130 
 Take Home Message…………………………………………………………….……131 
References………………………………………………………………….…………134 
ix 
 
Abbreviations and Acronyms 
 
ACAAffordable Care Act 
CDCCenters for Disease Control 
CHCCommunity Health Centers 
CVCCervical Cancer 
EBEmpirical Bayes 
FIPSFederal Information Processing Standard 
FQHCFederally Qualified Health Centers  
GISGeographic Information Systems 
HPSAHealth Professional Shortage Area 
HPVHuman Papillomavirus  
LISALocal Indicators of Spatial Association 
MLMMultilevel Model 
NPNurse Practitioner 
PCPPrimary Care Physicians  
PPHPlanned Parenthood  
RDCResearch Data Center 
SEERSurveillance, Epidemiology and End Results 
SESSocioeconomic Status 
USCSUnited States Cancer Statistics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
Chapter One 
Introduction 
Early detection and treatment of cervical cancer (CVC) can significantly reduce the probability 
of cancer mortality.
1
  Despite the advantage of early detection, preventive screening is 
significantly underutilized
2
 and 51% of women with CVC are diagnosed at a late stage (regional 
or distant).
3
  Late stage CVC diagnosis rates are disproportionate across various populations, 
with minority women and women in specific geographic regions reporting significantly higher 
rates.
4-8
  The cause(s) of these disparities are multifaceted and not well understood. However, the 
most significant predictor of stage at CVC diagnosis is current screening (i.e. having a Pap smear 
within the past three years) , which is a known proxy for access to care.
9-11
  
Several studies in the current literature suggest that the implementation of the Affordable Care 
Act (ACA) has helped to mitigate the issue of poor access to CVC screening by providing 
affordable insurance to more than 20 million individuals in the US.
12 ,13 
 In addition, the ACA 
mandated that health insurance plans were required to cover CVC screening in full, with no cost-
sharing. Although the ACA has made significant strides toward improving access to CVC 
screening,
14-15
 there are several factors and exclusions that reduce the potential for ACA 
mandates to have its intended effects.
16-17 
  Thus, the ACA has fallen short of eliminating 
screening access barriers for all women.  
These limitations along with the fact that significant disparities in stage at CVC diagnosis still 
exist, suggest the presence of additional factors influencing access to CVC screening and the 
pathways driving disparities in stage at CVC diagnosis. Thus, the purpose of this study is to 
contribute to this understudied body of literature by identifying access-related predictors of late 
stage CVC and developing a comprehensive understanding of where and why disparities in late 
stage CVC occur. Specifically, this study aims to apply unexplored model-based constructs and 
novel methodologies to determine whether racial and geographical disparities in late stage 
cervical cancer diagnosis exist (and persist) and how multilevel access barriers impact them. 
These multilevel access barriers include state Nurse Practitioner (NP) regulations, state cervical 
cancer screening mandates, PCP shortages, publicly funded health center density and the percent 
of the population in self-insured plans, all of which have never been explored in relation to stage 
2 
 
at CVC diagnosis or disparities. The ultimate goal of this study is to support progress toward 
eliminating disparities in late stage CVC diagnosis rates by pinpointing areas in greatest need of 
screening intervention, identifying significant access barriers and providing evidence for policy 
change and implementation. 
The investigation of these disparities will begin in Chapter 1. Chapter 1 will begin with a 
literature review to describe background information on the topic of cervical cancer (CVC), late 
stage CVC disparities and the role of access to care. Secondly, this study will describe theoretical 
and methodological problems/gaps in the current literature as it relates to the topic and 
innovative solutions to these problems. We will then describe the purpose of the study and how 
we plan to apply those innovative solutions to carry out three research aims. The following 
sections will describe the theoretical underpinning and the significance of the study.  
Literature Review 
Cervical Cancer Epidemiology & Prevention  
In previous years, cervical cancer was the second most common cancer among women.  In 90% 
of cases cervical cancer is caused by the Human Papillomavirus (HPV), a commonly occurring 
sexual transmitted disease.
18 
 Based on United States Cancer Statistics (USCS) data collected 
from 2010-2014 , there were 46,848 women alive in the US who were diagnosed with CVC.
19   
More recent data on cervical cancer incidence suggests that there were 12,845 new cases of CVC 
in the US in 2015.
19  
Compared to the CVC incidence rate of 9.6 per 100,000 in 2000, the overall 
age-adjusted incidence rate was 1.9 per 100,000 women lower in 2015.
19  
This decline can be 
attributed to two methods of cervical cancer prevention and early detection i.e. HPV vaccination 
and Pap testing.
20-21 
 As of December 2014, there were three vaccines available in the US to 
prevent HPV infection, Cervarix (HPV2), Gardasil  (HPV4) and Gardasil 9 (HPV9). According 
to the National Cancer Institute, the HPV vaccine can prevent up to 81% of new cervical cancer 
cases.
22
  In addition to the HPV vaccines, screening to detect and treat abnormal cervical cell 
changes (pre-cancers) before they potentially develop into cervical cancer (i.e. Pap testing) is 
also a well-known and available method for preventing cervical cancer. Due to early detection, 
cervical cancer has been found to be one of the most treatable cancers among all cancers.
20
 
 
Late Stage Cervical Cancer & Disparities  
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Despite the known effectiveness of Pap testing, 31% of women aged 18
2
 and over had not been 
currently screened for cervical cancer and 51% of women in Surveillance, Epidemiology and 
End Results (SEER) states who had been tested were diagnosed at a late stage (regional or 
distant).
3 
 Specifically, 36% of the CVC cases were diagnosed at regional stage where there is a 
regional lymph node metastasis and 15% at distant stage where there is a distant metastasis 
including peritoneal spread, involvement of supra-clavicular, mediastinal, or para-aortic lymph 
nodes, and spread to the bladder, lung, liver, or bone .
3,23  
Beyond the high incidence of late stage 
cervical cancer, it is even more alarming that the burden of late stage cervical cancers 
disproportionately affects some women  more  than others. Epidemiological surveillance 
indicates that unmarried
24   
foreign born
25
 and minority women
4-8
 have significantly higher odds 
of being diagnosed with late stage cervical cancer compared to their counterparts. Epidemiologic 
studies have also found that women in specific geographic regions and women over age 50 
4-8 
have greater odds of late stage cervical cancer compared to others.
8
  
Among these disparities, geographic and racial disparities have been most persistent across 
various populations in the US According to an early time trends study, the odds of late stage 
cervical cancer among African American women increased over a 15 year time period (1976 -
1990).
11 
 A later 2009 analysis of SEER data reported that African Americans were diagnosed at 
more-advanced stages than Whites for all four cancers with widely recommended screening 
procedures, including cervical, breast, colorectal and prostate cancer.
6
  A 2011 MMWR also 
reported that the incidence of late stage cervical cancer was nearly two times as high among 
Hispanic compared to White women, 8.4 per 100,000 vs 4.9 per 100,000 respectively.
8 
  
Previous research further suggests that disparities in late stage CVC incidence exist between 
different geographic populations.
4,9-11,26 
 In fact, there is scientific evidence that suggests that 
there is extreme variability in the rates of late stage CVC at both the census tract and state level. 
For example, a 2014 study found that there was significant variability in stage at CVC diagnosis 
among 4,388 census tracts in the state of Texas (TX).
26
 Major findings from this study indicate 
that clusters with statistically significantly increased risk for late stage CVC were located in the 
Western tip of TX, Southern TX, the Bryan/College State area and central Houston.
26
 In regards 
to the state level, evidence suggests that late stage cervical cancer incidence rates were highest in 
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Arkansas, the District of Columbia, Illinois, Kentucky, Louisiana, Mississippi, Nevada, New 
Mexico, and Oklahoma.
8 
Factors Impacting Late Stage Cervical Cancer 
The current literature assessing predictors of late stage cervical cancer incidence identifies socio-
economic status (SES), insurance coverage, insurance type, and current screening as factors 
associated with late stage cervical cancer.
27-32
  A bivariate analysis conducted in early 2000 using 
Florida state cancer registry data found that patients with lower income levels had a greater 
likelihood of late stage cervical cancer compared to those with higher income levels (52% vs 
33.3%; P.04).
27
  A later study published in 2014, using 1995-2008 data from the Texas Cancer 
Registry found that the odds of advanced stage cervical cancer among patients in census tracts 
with the lowest SES were 1.54 times the odds of advanced stage cervical cancer among those in 
census tracts with the highest SES. 
26  
 
A more recent 2016 multivariate analysis using 2007-2011 SEER data found that patients who 
were uninsured were 1.21-2.03 times more likely to be diagnosed with distant site  cervical 
cancer compared to those who had insurance coverage.
28 
 Another study using the National 
Cancer Database suggests that the relative risk of late stage cervical cancer diagnosis among 
uninsured patients is  1.44 times the risk of late stage cervical cancer diagnosis among those with 
insurance coverage.
29  
This study also found that the relative risk of late stage cervical cancer 
diagnosis among those enrolled in Medicaid is 1.37 times the risk of late stage cervical cancer 
diagnosis among those that were privately insured.
29  
 Similarly, research using California 
Registry data collected between 1996-1999 also found that the odds of late stage cervical cancer 
among those enrolled in Medicaid insurance was 2.8 times the odds of late stage cervical cancer 
among those not enrolled in Medicaid insurance.
30 
 
  
Finally, a 2015 study using data from the National Breast and Cervical Cancer Early Detection 
Program found that those who were rarely or never screened were 3.59 times more likely to be 
diagnosed with late stage cervical cancer compared to those who had been screened within that 
past 5 years.
31 
 Another more recent 2018 study among cases reported by the Outpatient 
Obstetrics and Gynecology clinic also found that the adjusted odds of late stage cervical cancer 
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diagnosis among those without  a history of previous screening was 3.91 times the odds of  late 
stage cervical cancer diagnosis among those who had a history of previous screening.
32 
The Role of Access in CVC Screening 
Research suggests that the most significant predictor of late stage diagnosis is current screening, 
which is largely impacted by access to care.
9-11 
Access is defined as “the timely use of personal 
health services to achieve the best health outcomes.”
33 
Health care access has also been defined 
as “the opportunity or ease with which consumers or communities are able to use appropriate 
services in proportion to their needs.” 
34 
  It can further be defined by three constructs: 
availability, accessibility and affordability.
35-36 
  This experience of access has been unequal 
across various individuals and places in the United States.
36 
  In fact, access to care is often 
determined by one’s race, ethnicity, socioeconomic status, age, sex, disability status, sexual 
orientation, gender identity, and residential location.
37 
  Research suggests that individuals facing 
the greatest barriers to obtaining basic health care services report negative health outcomes at a 
disproportionately higher rate .
38
   
According to the literature there a number of personal and structural barriers associated with 
inadequate access to care and lower CVC screening rates in the US Several studies suggest that 
recent immigration status and poor language proficiency are barriers to CVC screening among 
Hispanic populations.
39-40 
 A 2017 multivariate analysis of predictors of barriers to CVC 
screening among low income and uninsured women enrolled in the Texas Cancer Screening, 
Training, Education and Prevention Program found that Hispanic women were 4.72 times more 
likely to report language barriers to CVC screening, compared to Whites.
41  
The literature also 
suggests that living in rural geographical locations is also a barrier to CVC screening. 
Specifically, women in rural areas and economically deprived non-rural communities are less 
likely to be screened for CVC and report lower screening rates compared to women in urban and 
suburban areas with higher incomes.
39
 Another 2014 survey study investigating rural populations 
and CVC screening also found that 71% of rural Appalachian respondents reported “not being 
able to use public transportation to get to medical appointment” as a barrier to screening.
42 
 A 
2016 review of the literature describing CVC screening barriers among minority women also 
found that inadequate knowledge of CVC screening and provider relationships were both barriers 
preventing adequate screening rates among African American and Hispanic women.
43 
 Similarly, 
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a survey study published in 2016 also found inadequate knowledge to be a significant predictor 
of not receiving a Pap test
44 
 Specifically, regression analysis found that the odds of Pap testing 
among women with knowledge regarding the test was 1.63 times the odds of testing among those 
didn’t have knowledge regarding Pap smears.
44 
The literature also suggests that cost, affordability and usual source of care play important roles 
in access to CVC screening. In fact, an early 2003 study examining access barriers to 
preventative services using data from the Medical Expenditure Panel Survey found that women 
ages 21-64 who were uninsured and without a usual source of care were less likely to receive a 
Pap test.
45
 Specifically, women who had a primary care provider were 2.06 times more likely to 
have a Pap test compared to women who had no usual source of care.
45
  This study also reported 
that women with private HMO insurance were 3.95 times more likely to have a Pap test 
compared to women with no health insurance.
45
  This study further concluded that differences in 
access to care measures were the drivers of the disproportionately lower receipt of Pap testing 
among minority women compared to White women.
45 
 
  
Another study published in 2003 aiming to identify the relationship between access and Pap 
smear screening practices among Latino women in California also found insurance and usual 
source of care to significantly influence screening.
46
  Results of this study suggest that Latino 
women who were insured were twice as  likely to have a Pap test compared to those that were 
not and Latino women that had a regular source of health care were 1.8 times more likely to have 
a Pap test compared to those that didn’t have a usual source of care.
46 
 A 2007 systematic review 
of 17 studies focusing on factors inhibiting and promoting cervical cancer screening among 
African American and Hispanic women concluded that lack of health insurance, usual source of 
care and SES were significant determinants of screening.
47
  Among the 17 studies, 41% reported 
lack of insurance as a barrier to cervical cancer screening, 41% reported lack of a usual source of 
care as a barrier and almost all of the studies reported that SES was a barrier to cervical cancer 
screening.
47 
 A later 2017 multivariate analysis of predictors of barriers to CVC screening among 
low income and uninsured women enrolled in the Texas Cancer Screening, Training, Education 
and Prevention Program also found that 61.6% of respondents reported cost as a barrier to Pap 
testing.
41 
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Previous ecological studies have also found that similar compositional and contextual factors are 
associated with disproportionate CVC screening and late stage CVC rates among geographic 
areas.
48-53
 Among these factors are area level socioeconomic status (SES)
26,
 
48
and community-
level age, race and immigrant composition.
26,49
 Studies have also shown that contextual factors 
impacting access to care are associated with CVC screening and stage at diagnosis.
26,50-52
 
Specifically, the literature suggests that health services resources in the community, travel time 
to the nearest screening facilities and availability of services in the community represent 
contextual access to care factors associated with CVC screening and stage at diagnosis. 
26,52-53
 
The Affordable Care Act & Access to CVC Screening 
The implementation of the Affordable Care Act (ACA) has helped to mitigate the effects of poor 
access to CVC screening by providing affordable insurance to more than 20 million individuals 
in the U.S beginning in 2014.
13 
In addition, the ACA mandated that all health insurance plans 
were required to cover CVC screening in full, with no copayment or out of pocket costs to 
insureds beginning in 2012.  As a result, the ACA has been found to be associated with increased 
CVC screening rates and early stage diagnoses.
14-15 
In 2016 a study reported that the ACA was 
associated with a 21.2% increase in early stage (stage I) cervical cancer diagnoses among cancer 
patients aged 19-25 years.
14 
A later 2017 systematic review also found that the ACA had a 
significant impact on cancer screening, including Pap tests, among 14 studies.
15
  
Although the ACA has made significant strides toward improving access to CVC screening, it 
has not eliminated access barriers for all women. Following the implementation of the ACA 
there were still 44.4 million individuals left uninsured and thus potentially facing issues 
regarding affordability of care.
54 
 Furthermore, due to expanded insurance coverage provided by 
the ACA, the need for primary care physicians (PCP) is expected to increase to as many as 
49,300 PCPs by year 2030.
55
  This presents an issue of availability of care for several women, 
including those with insurance, as the US is already experiencing a climate of primary care 
physician shortage.  
Further, although health insurance plans that were in place prior to the passing of the ACA were 
allowed time to come into compliance with ACA provisions before being permanently excluded,  
exclusions and loopholes were widespread.
16-17 
 One such loophole allowed ‘grandfathered’ 
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plans in states with no prior mandate for CVC screening to be exempt from the ACA mandated 
coverage of CVC screening.
17 
 For a limited time period, individuals in ‘grandfathered’ self-
insured plans were also exempt from many of the ACA provisions; a population that accounts 
more than 50% of persons with employer-sponsored health insurance.
56 
 Together these 
exclusions reduce the potential for ACA mandates to fully achieve their intended effects. These 
factors together with the persistence of significant disparities in CVC screening and stage at 
diagnosis, suggest the presence of unexplored and interconnected forces influencing access to 
CVC screening and pathways to late stage CVC diagnosis. 
Problem Statement: Limitations in Literature 
The source(s) of geographic and racial disparities in late stage cervical cancer incidence are 
multifaceted and not well understood. However, there is a well-documented link between 
inadequate access to care and health disparities.
11   
In fact, inadequate access to essential health 
care services was listed as one of the most important determinants of health disparities as early as 
1991.
57
  While several studies have helped to advance our understanding of disparities in stage at 
CVC diagnosis and their relationship with access to care, the majority of the studies in the 
literature are outdated, include a small sample of the US population, and present notable 
limitations in their modeling approach.  
We believe late stage CVC diagnosis rates and disparities are predicted by interactions among 
people and characteristics of their contextual environments which include varying dimensions of 
access to care. Thus, to properly model the etiological pathways to these outcomes we must 
consider the influence of the multiple constructs of access to care,  the multiple levels in which 
these constructs exist and their spatial interactions with various compositional and contextual 
factors. This proposal aims to shift current research or clinical paradigms related to racial and 
geographical disparities in stage at cervical cancer diagnosis and the relationship between these 
disparities and various dimensions of access to health care by utilizing data representing 43 of 
the 50 states and applying unexplored model-based constructs and novel methodologies and 
spatial perspectives.  
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Unexplored Constructs of the Access Framework 
Based on Aday and Andersen’s access framework developed in 1974, access can be determined 
by assessing the influence of health policy on characteristics of the population at risk and 
characteristics of the health delivery system, which in turn influences both utilization of health 
services and customer satisfaction.
58
  In this framework the health policy construct represents 
relevant health policy and health care reorganization programs aimed at improving access to 
health care.
58
 The characteristic of the population at risk construct includes factors such as: age, 
sex, race, religion, family income, insurance coverage, rural/urban character, attitude toward 
medical care and perceived need for care.
58 
 The characteristics of the health delivery system 
construct includes: health personnel, structures in which health care and education are provided, 
the equipment and materials used in providing health services, volume and the distribution of 
medical resources in an area, travel time, waiting time, and how a patient is treated.
58 
 Finally, 
utilization of health services rates and customer satisfaction scores are referred to as outcome 
indicators representing an individual’s passage through the system.
58 
With guidance from this model, several studies in the literature have focused on one or more of 
these constructs to explain the issue of access in regards to some health service. In regards to the 
literature on access barriers influencing cervical cancer screening, there is a focus on only two of 
the three access dimensions mentioned in the access framework: characteristics of the population 
at risk or in very few cases characteristics of the health care delivery system. As described in the 
above literature review, access to screening is mainly associated with characteristics of the 
population at risk such as insurance status, SES, immigration status, language proficiency, 
rural/urban status and knowledge. This literature review also highlights a few characteristics of 
the health care delivery system that impact access to CVC screening such as the patient-provider 
relationship, transportation to the nearest provider and usual source of care.
  
However, there are additional access indicators underlying characteristics of health policy and 
the health care delivery system that likely influence current screening and stage at CVC 
diagnosis, yet they have been left unexplored. These factors include state policies regulating 
health professionals’ ability to provide care and state insurance mandates requiring cervical 
cancer screening coverage, which represent factors underlying the health policy construct and 
primary care physician shortage and publically funded health center density, which represent 
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factors underlying the characteristics of the health delivery system construct. The distribution of 
each of these factors varies from place to place and their individual and interacting effects could 
potentially explain the persistent racial and geographical disparities in late stage cervical cancer 
incidence. 
Primary Care Physician Shortages & Underserved Populations  
Over time data has consistently demonstrated an unmet need of primary care physicians in the 
US According to the Association of American Medical Colleges (AAMC), there was an 
estimated 91.7 primary care physicians per 100,000 people in the US in 2016.
59
  This translates 
to a total supply of approximately 296,353 primary care physicians.
59  
Considering the current 
supply, there were still 7,176 designated primary care health professional shortage areas (areas 
with <1 primary care physician per 3,500 people) in the US in 2017.
60 
 Current HRSA reports 
project that this shortage will worsen as the population grows and as expanded insurance 
coverage provisions of the Affordable Care Act take effect.
55
 In fact, the PCP shortage is 
expected to increase to a range between 14,800 and 49,300 primary care physicians by year 
2030.
55 
The primary care physician shortage is of grave public health significance as leaving individuals 
without readily available care can impact a wide range of health outcomes. Research suggests 
that for every additional PCP per 10,000 people there is a 5.3% decrease in all-cause mortality 
per year.
61
 Research further suggests that the physician shortage is a key determinant of 
disparities in access to care. With over 100 million Americans living in a defined geographic 
area with a shortage of primary care health physicians (i.e. medically underserved)
62
, these 
individuals report a lower quality of health services and are less likely to receive  routine medical 
procedures, including screening.
63
  In fact, compared to women living in areas of higher 
physician density (500 or more office-based primary care physicians per 100,000), women who 
live in areas of lower physician density (<100 office-based primary care physicians per 100,000 
women) were significantly less likely to receive a Pap test in the past 3 years.
64-65 
Nurse Practitioner Regulations 
Although many incentives have been proposed to increase the number of primary care 
physicians, one of the most plausible solutions to the PCP shortage is the use of nurse 
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practitioners. 
 
Nurse practitioners are advanced practice nurses that receive training and enter the 
health care system in less time and have been shown to provide quality at lower costs per visit 
compared to their physician colleagues.
66 
 A number of studies and systematic reviews have 
shown that NPs score higher on measures such as patient follow up, time spent in consultations, 
and provision of screening, assessment, and counseling services, compared to physicians.
67 
 
According to the American Academy of Nurse Practitioners there are approximately 140,000 
NPs in the US.
68 
 With over 50% of the NP workforce practicing in primary care settings,
69
 NPs 
are among the top health professionals providing  primary care services in family planning 
clinics.
70 
  Compared to physicians, nurse practitioners have also been found to be the majority 
provider type in rural and underserved populations.
71 
 Overall, the addition of NPs has not only 
increased overall access to health care
72 
 but it has been associated with reaching unscreened and 
under-screened women and those women lost to follow-up.
68
  
Despite the known benefits of using NPs to address the access barriers associated with the 
existing physician shortage, there are several barriers these providers face in practicing to the full 
scope of their training. Among these barriers are state-based regulations limiting NPs’ scope of 
practice. While some states allow NPs full independent scope of practice (evaluate, diagnose, 
treat, and prescribe under the exclusive licensure authority of the state board of nursing), others 
impose restrictions on NP practice, including supervision, delegation,  team management by a 
physician or restrictions in at least one element of practice.
73
 Recent data indicates that 22 states 
and the District of Columbia allow NPs full practice and 29 states impose restriction on their 
practice.
73 
Many argue that complying to restrictive scope of practice laws could take time from 
both NPs and their supervising physicians
74 
and limit the supply of health services.
75  
Several 
organizations including the Institute of Medicine recommend removing these restrictions as they 
believe “optimal utilization of NPs could increase patients’ access to timely high-quality, cost-
effective, patient-centered care.”
76-77 
In support of their claims, research indicates that states with 
full or less restrictive NP scope of practice laws are associated with increased office visits
69 
and 
better access to quality care.
78 
Community Health Centers & Publicly-Funded Clinics 
Community health centers  (CHC) were developed with the specific goal of providing high 
quality and comprehensive primary care to medically underserved populations, regardless of 
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their ability to pay.
79-80 
 Both CHC and other publicly- funded health clinics provide free or low-
cost services through a number of publicly-funded programs such as the Title X national family 
planning and Medicaid programs.
79 
 Grantee sites include federally qualified health centers 
(FQHC), planned parenthood affiliates, public health departments, hospitals and other health care 
providers. These sites provide a wide range of primary and preventive services, including 
cervical cancer screening, to individuals that are disproportionately uninsured, low income and 
racial and ethnic minority.
81 
Community health centers and other publicly-funded clinics are not evenly distributed across the 
US and many have been shut down due to lack of government funding.
82 
  Some states have as 
many as 176 community health centers while others have a few as four.
79 
 Community health 
centers are essential to public health as they have been found to play a critical role in expanding 
access to care and reducing health disparities among their patient population of nearly 27 
million.
79
  In regards to cervical cancer, Title X-funded centers alone (including both CHC and 
publicly-funded clinics)  were responsible for providing affordable CVC screening to more than 
743,000 female clients across 3,900 Title X-funded health clinics in 2015.
81 
 Data also suggests 
that community health centers, irrespective of public funding source, have been successful in 
expanding access to CVC screening and reducing related health disparities among their 
socioeconomically and racially diverse patient populations. In fact, health centers have provided 
4% more Pap smear services over the last 3 years compared to other health providers, 85% vs 
81% respectively.
79 
 Data also suggests that 92% of Hispanic women in need of Pap testing at 
health centers received these services compared to only 69% of Hispanic women in need of these 
services nationally actually received them.
79 
 Similarly, 89% of African American women in 
need of Pap test at health centers actually received these services compared to only 75% of 
African American women in need of these services nationally who actually received them.
79 
State CVC Screening Insurance Mandates& Self Insured Plans 
Since the early 1960s, requirements regarding coverage provisions of private health insurance 
policies have largely fallen under the jurisdiction of state governments.
83   
Mandated state 
insurance coverage requirements were established in efforts to promote public health and 
improve access and treatment for people with specific diseases, including cancer. State cancer 
mandates now include requirements for screening, prevention and treatment.
83   
In 2009, there 
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were approximately 25 cancer-related state insurance mandates.
83 
Among those mandates, only 
two focused on cervical cancer, required coverage for cervical cancer screening and HPV 
vaccination. In this regard, there was significant variation across states. By 2009, 32 states and 
the District of Columbia required insurers to cover cervical cancer screening while 19 did not.
83 
  
While state CVC screening mandates are now perhaps less important, following the 
implementation of new preventive services coverage provisions under the Affordable Care Act 
(ACA) from 2012-2014, there are still reasons to expect that they may be significant predictors 
of late stage CVC.  First, they established a stronger baseline in states that adopted them prior to 
2010 that was absent in other states. Thus, these states were poised to perform better than states 
who saw these requirements for the first time in 2010. Several other factors suggest the 
importance of state mandates in supporting access to healthcare.
16, 83-86
 For example, private 
health plans that existed prior to March 23, 2010 were considered ‘grandfathered plans’ and were 
exempt from required coverage for preventive services under the ACA, including CVC 
screening.
16 
 Similarly, commercial health insurance inside and outside of the health insurance 
exchanges are exempt from the ‘no cost sharing’ feature of the preventive services provisions 
under the ACA when preventive services are not delivered by a network provider.
85 
These types 
of loopholes reduced the potential for federal ACA mandates to achieve their intended effects on 
access to healthcare by exempting large portions of the insured population. Furthermore, a 
systematic review of studies investigating the ACA’s impact on cancer screening and diagnosis 
found that the impact on changes in screening in the general population was mixed.
86
 Together 
these loopholes and findings suggest that state mandates may still play a significant role in 
access to healthcare post-ACA implementation in 2010. 
In 2013, Miles-Richardson et al. examined the impact of state cervical cancer screening 
mandates on screening rates and racial disparities in screening rates among women in Georgia, 
North Carolina and South Carolina and found no significant effects.
87 
However, a later 2017 
study found that Pap test mandates increased past 2 year screening by 1.3 percent.
88
 This study 
also indicated that the effects of these mandate on screening rates were significantly larger 
among Hispanic women.
88 
We believe findings suggesting a relationship between CVC screening and state cancer-related 
insurance mandates have been inconsistent because there may be significant lags in effects, so 
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later studies may find larger effects.  Also, studies have not considered  important contingencies 
related to private sponsorship of self-insured plans,  although these plans account for more than 
50% of persons with employer-sponsored health insurance.
89
 According to provisions under the 
Employee Retirement Income Security Act (ERISA), self-funded employer plans are exempt 
from most state insurance laws, including mandated benefits.
16
 However, self-funded plans 
established by public employers are not exempt from state insurance laws.
16 
  Thus the effects of 
these mandates by states may depend upon how much of the self-insured population is in public 
or private plans. 
Multilevel Modeling  
In addition to the lack of available studies assessing the impact of factors representing the 
multiple constructs of access to care, current research investigating disparities in stage at CVC 
diagnosis and access to CVC screening has also failed to account for the simultaneous effect of 
factors occurring at multiple levels. In fact, several researchers have reported that despite efforts 
to change, many health disparity studies have continued to focus solely on individual level 
explanations and have failed to include explanations of the spatial processes and pathways to 
health outcomes.
90-92
  This limited approach prevents researchers from understanding that many 
health outcomes such as access to screening and subsequent disparities in stage at diagnosis are 
influenced by complex and interacting social, environmental and behavioral processes that occur 
at varying geographical and socioecological scales.
93 
 As described in Aday and Andersen’s 
access framework, access can be determined by assessing the influence of health policy, 
characteristics of the health delivery system, and characteristics of the population at risk, all of 
which occur at varying socio ecological levels.
58
   
Further examination of the access framework demonstrates that these factors could also lie on 
various geographical levels. For example, in most cases health policy varies by state and thus 
occurs at the state level, and characteristics of the health delivery system commonly vary by 
hospital/clinic and thus occur at a lower level such as county or region. Considering the 
hierarchical structure of the data allows researchers to simultaneously examine the effects of 
individual and group level variables and the interactions within and between them.
94 
 Further, 
this approach allows researchers to more accurately model reality by accounting for non-
independence of individuals within groups.
94-95  
Finally, using this approach when appropriate 
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allows researchers to adjust for spatial heterogeneity or clustering thereby ensuring that standard 
errors and p-values for the estimated regression parameters are unbiased and the correct 
inferences are made. Ultimately, exploring the relationship between place-based contextual and 
compositional factors and health outcomes using multilevel models has proven to be extremely 
useful in understanding complex health issues.  
Despite the efficiency of multilevel modeling, a review of the literature indicates that most of the 
studies on this topic limit their investigations to one level of influence at a time
90-92, 96 
and with 
the exception of the impact of the ACA, typically understudy the effects of several factors that 
lie at the health policy level.  In fact, no study was found using multilevel modeling to 
understand multilevel access barriers and their effects on late stage CVC diagnosis. However, 
multilevel modeling has been used to assess other cervical cancer-related outcomes including: 
CVC screening, CVC incidence, CVC mortality, HPV coverage, and immune response to HPV 
vaccines. Among these studies, insurance status and percent living in poverty were the most 
commonly used access to care indicators. In fact, a 2005 study conducted by Datta et al. used 
multilevel modeling to examine individual, neighborhood, and state level predictors of cervical 
cancer screening among African American women in the US.
97
  This study evaluated the effects 
of several covariates, however, insurance status and percent living in poverty were the only 
access indicators included in the model.
97  
A more recent 2103 study also used a multilevel 
random intercept model to assess the impact of individual, county and region-level variables on 
HPV vaccination coverage among women in Texas.
98
  This study also tested the effects of 
percent of uninsured and percent of total population in poverty.
98
  A 2013 dissertation study also 
used multilevel modeling to investigate the effects of individual, area and county level factors on 
cervical cancer incidence among women in Appalachia Ohio.
99 
 Similar to previously mentioned 
studies, percent without health insurance and childhood poverty were the only access to care 
indicators included in this model.
99  
Although none of these studies obviates the need for our 
research, Coughlin et al.’s study most closely aligns with our research study as they use the 
multilevel approach to examine the effects of individual and county level factors associated with 
health care access on breast and cervical cancer screening among women in the US.
100 
 These 
factors included health insurance coverage, residence in health professional shortage areas, and 
the number of health centers/clinics and primary care physicians.
100
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Spatial Analytic Methods & Perspective
 
Finally, the literature suggests that advanced spatial analytic methods and perspectives have not 
been frequently applied to identify or generate hypotheses regarding the factors underlying racial 
and geographical disparities in stage at cervical cancer diagnosis. This is due in part to lack of 
knowledge regarding the utility of spatial data, lack of appropriate spatial databases and 
previously insufficient spatial analytic software.
101  
As a result, previous research on this topic 
largely underestimates the contribution of place; a “ social context deeply connected to larger 
patterns of social advantage and disadvantage.”
102 
Considering the contribution of place is essential to understanding health outcomes. Using 
spatial methods, researchers have assessed the distribution of disease incidence, mortality and 
stage at diagnosis rates across geographic regions to identify disparities and generate hypotheses 
regarding significant factors underscoring various health outcomes. In fact, a spatial method 
called Local Indicators of Spatial Association (LISA) testing allows researchers to evaluate area 
differences in rates of health outcomes by pinpointing spatial clustering of these rates at the 
county level. Specifically, counties are grouped into four distinct spatial cluster types: high-high, 
low-low, low-high or high-low clusters. If both a county and the spatial lag of that county (i.e. 
the average rate of all the defined neighbors of a county) are lower than the national average rate 
and there is a statistically significant correlation between them, it is classified as being within a 
low-low cluster (i.e. coolspot).  Similarly, if both a county and the spatial lag of that county are 
higher than the national average rate and there is a statistically significant correlation between 
them, it is classified as being within a high-high cluster (i.e. hotspot). By focusing on clustering 
of counties with higher than average rates of a selected health outcome that are surrounded by 
neighboring counties with higher than average rates of that same outcome “hotspots,” 
researchers can determine 1) whether there are geographic disparities in the selected health 
outcome, 2) whether these geographic disparities persist over time and 3) whether they are 
associated with various contextual and compositional factors.  
Based on a thorough review of the literature, this approach has never been applied to 
understanding disparities in late stage cervical cancer diagnosis and their associated risk factors. 
However, a similar approach has been applied to the investigation of disparities in cervical 
cancer incidence. Roche et al. used New Jersey state cancer registry data and applied spatial scan 
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statistics to identify spatial clusters of census tracts with high cervical cancer incidence.
103 
 After 
identifying these geographical disparities they used logistic regression to examine risk factors 
associated with being a census tract in a high rate cluster.
103  
Similarly, a study conducted by 
Saghari et al. used geographic information systems (GIS) to evaluate spatial clustering of both 
cervical cancer incidence and SES in California.
104
 To determine whether there was an 
association between patterns, the authors then tested spatial cross correlations between the 
identified cervical cancers incidence and SES clusters.
104  
These examples demonstrate the 
usefulness of spatial methodology in understanding disparities in cervical cancer outcomes. 
Summary of Limitations 
The current literature evaluating disparities in late stage cervical cancer diagnosis is limited in a 
number of ways. Specifically, neither advanced spatial analytic methods nor multilevel modeling 
have been applied in studies aiming to identify factors underlying racial and geographical 
disparities in stage at cervical cancer diagnosis. Yet, both of these methods have been proven 
useful for public health surveillance and understanding disease etiology and disparities among an 
array of other health outcomes. 
 
Review of the existing literature on access to CVC screening and 
late stage CVC diagnosis also demonstrates that the impact of several constructs of the Access 
Framework has been left unexplored.  However, using a thorough list of factors identified 
through the access to care framework is necessary for conceptualizing and gaining a 
comprehensive understanding of the impact of multilevel access barriers experienced along the 
pathway to late stage diagnosis. Finally, no study has used nearly complete US data (n=43 states) 
to explore these disparities and underlying factors. Most of the studies used single state registry 
data or SEER data, which only includes complete data from 12 states. 
Statement of Purpose & Research Aims 
The purpose of this study is to develop a comprehensive understanding of where and why 
disparities in late stage cervical cancer occur. Specifically, this study aims to determine whether 
racial and geographical disparities in late stage cervical cancer diagnosis exist (and persist) and 
how multilevel access barriers impact them. Further, this study aims to highlight the relationship 
between inadequate access to care and disparities in late stage cervical cancer diagnosis. Using 
access-related contextual and compositional factors as a focus, we plan to develop a better 
understanding of how to best intervene, who is in greatest need of intervention and how to better 
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inform health policy. Ultimately, these efforts will contribute to the long term goal of reducing 
disparities in late stage cervical cancer diagnosis and the resulting disparities in cervical cancer 
mortality. 
This study will include cervical cancer cases diagnosed from 2005-2014 from the United States 
Cancer Statistics (USCS) database, available at the National Center for Health Statistics 
Research Data Center.
105 
 The USCS database is a population-based surveillance system of 
cancer registries with data representing 98% of the US population.
105
  This database has 
information on demographics (age, gender, race, and ethnicity), tumor characteristics, and 
geographic location (county of residence) at time of diagnosis.
105 
 The confidentiality of data 
with geographic identifiers for county of residence is preserved by restricting access to 
researchers with approved research plans with analyses conducted inside secure federal Research 
Data Centers (RDCs). There is no access to the Internet from inside the RDC, and all results 
must be reviewed before they can be released from the RDC and published.
105 
All states participate in the USCS registry system, however, five states do not allow use of 
county of residence information (Kansas, Minnesota, Illinois, Michigan and Missouri).
105 
Therefore, we will exclude these five states and two additional states, Alaska and Hawaii, 
because of missing contextual data. Our final analysis will include 43 states and each of their 
counties. The study sample will be further restricted to exclude cervical cancer records when 
these cases were not their primary cancers or when records featured unknown cancer stage or 
unstaged cancer. This restriction resulted in 120,325 cervical cancer cases between 2005- 2014.  
Using this data we plan to carry out the following specific aims: 
Specific Aim 1 - Using data representing 43 of the 50 states, we will identify and 
characterize clusters of counties considered to be high risk “hotspots” and clusters of 
counties considered to be low risk “ coolspots”, during two 5 year  time periods (pre- and 
post-2010). Under this aim, we will also determine whether the hotspots identified in both 
time periods are associated with various contextual and compositional factors and whether 
there were hotspots that persisted over both time periods. To identify spatial clustering of 
county level late stage cervical cancer diagnosis rates during two time periods we will use a 
spatial cluster method called Empirical Bayes (EB) adjusted LISA. This method first corrects for 
variance instability among late stage CVC rates and then computes local spatial autocorrelation 
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statistics.  Specifically, the EB- adjusted LISA test will calculate a test statistic for each county 
indicating whether the late stage cervical cancer incidence rate in that county is statistically 
significantly higher or lower than the national average. If both a county and the spatial lag of that 
county (i.e. the average rate of all the defined neighbors of a county) are statistically significantly 
higher than the national average rate, it is classified as being within a hotspot cluster. Similarly, 
if both a county and the spatial lag of that county are statistically significantly lower than the 
national average rate, it is classified as being within a coolspot cluster.  
To determine whether the identified clusters are associated with various contextual and 
compositional factors we will employ a series of t-tests. Specifically, for both periods, all hotspot 
clusters will be grouped together and all coolspot clusters will be grouped together and treated as 
two independent groups. We will then test for statistically significant differences in underlying 
compositional and contextual factors between the two groups (hot and coolspots clusters).  
Finally, to determine whether there were geographic hotspots that persisted over both time 
periods (worse places) we developed a colocation map. To develop the colocation map we 
grouped counties into three categories: those that belonged to significant hotspot clusters in both 
periods (persistently hotspots), those that did not belong to significant hotspot clusters in either 
period (persistently non-hotspots), and those that transitioned into or out of a hotspot clusters 
(transitional hotspots). The coincidence of these three categories across the two time periods 
were then mapped using QGIS software (formerly known as Quantum GIS).   
It is our hypothesis that there will be spatial clusters of higher than expected late stage cervical 
cancer diagnosis rates and that these clusters will differ across the two time periods. We also 
predict these clusters will contain geographic factors that can help better explain why late stage 
CVC varies across counties in the US and how risks change over time. Thus, identifying spatial 
patterns will ultimately allow us to better isolate risk factors and generate realistic and testable 
hypotheses regarding the relationship between “hotspots” and contextual/compositional factors 
that may underscore significant inequities in stage at CVC diagnosis and access to CVC 
screening services. Finally, identifying patterns in late stage cervical cancer will allow 
researchers to target areas in greatest need of intervention and better allocate intervention 
resources. 
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Specific Aim 2- Using data representing 43 of the 50 states from the interval 2010-2014, we 
will examine the relationship between late stage cervical cancer diagnosis and various 
individual- and county - level access predictors, with a primary focus on primary care 
physician (PCP) shortage and the number of community health centers (CHCs) and other 
publicly funded clinics. Considering that minority communities are disproportionately 
represented among medically underserved populations and that publicly funded clinics 
predominately serve minority populations, we also aim to determine whether the 
relationships between  the number of Planned Parenthood clinics per 100,000 people and 
CVC stage at diagnosis and PCP shortages and stage at CVC diagnosis  differ by race or 
ethnicity. With patients nested within counties, we expect that stage at cervical cancer diagnosis 
will be clustered within the spatial contexts of county.  Thus, we will fit a two-level random-
intercept logit model to examine various individual- and county-level predictors of late stage 
cervical cancer diagnosis.  
Individual level predictors will include age and race or ethnicity. County level predictors will 
include number of CHCs and other publically funded health clinics per 100,000 people (Planned 
Parenthood (PPH) clinics and Federally Qualified Health Centers (FQHCs)), primary care 
physician shortage , percent uninsured, percent poverty, percent HMO penetration,  previous 
country of residence and population density as a measure of urbanicity. We will also estimate 
two separate multilevel models each with the aforementioned covariates and a single cross-level 
interaction. One model will include a cross-level interaction between race or ethnicity and PCP 
shortage and the other will include a cross-level interaction between race or ethnicity and PPH 
clinics. Final random and fixed parameter estimates will be calculated using Maximum 
Likelihood estimation methods in SAS 9.2 statistical software. This model will provide national 
level estimates of the probability of late stage CVC given various access indicators.  
Specific Aim 3- Using data representing 43of  the50 states, we will identify county-level 
disparities in late stage CVC across (n=43 states) and explain the observed disparities by 
identifying statistically significant ecological relationships between high proportions of late 
stage CVC diagnoses in counties and several county and state-level variables during the 
time interval 2010-2014. Using a hybrid model that draws from the Access to Care 
Framework, Theory of Access and Socio-ecological model, we specifically explore the 
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relationships between late stage CVC and several indicators of access to CVC screening. 
Among the study variables we are most interested in are unexplored access to care factors 
that are determined by state policy including: state policies regarding scope of practice for 
nurse practitioners, state healthcare insurance CVC screening mandates and state-level 
proportions of individuals enrolled in self-insured employer-sponsored insurance plans. 
With counties nested within states, we believe that stage at cervical cancer diagnosis will be 
clustered within the spatial contexts of state. Thus, we will fit a two-level random-intercept logit 
ecological model to examine various county and state level predictors of late stage cervical 
cancer diagnosis.  
County level predictors will include the following contextual variables: number of PPH clinics, 
FQHCs, and Title X funded centers, Health Professional Shortage Area (HPSA) score, percent 
persistently poor, percent that speak English poorly and population density as a measure of 
urbanicity. County level predictors will include the following compositional variables:  age and 
race or ethnicity.  State level predictors will include Nurse Practitioner (NP) regulations, CVC 
screening mandate, percent of state underserved by primary care providers, percent screened for 
CVC and proportion insured by employers in self-insured plans exempt from state regulation. To 
identify interactive relationships associated with geographic disparities in late stage CVC 
diagnosis, we will also include a cross-level interaction between CVC screening mandates and 
percent in self-insured plans. Because private self-insured plans can avoid the protective effect of 
state health insurance mandates, we hypothesize that states with both CVC screening mandates 
and higher proportions of the state population in private self-insured plans will be associated 
with high county-level proportions of late stage CVC. Final random and fixed parameter 
estimates will be calculated using Maximum Likelihood estimation methods in SAS 9.2 
statistical software, which will allow for state intercepts to vary.  
To visualize geographic disparities in the proportion of late stage cervical cancer across counties, 
we will also spatially translate proportions onto a US map. Mapping will be done in QGIS 
software using standard deviation features which groups proportions by how many standard 
deviations (<2 sd : >2 sd) they are from the national estimate. It is our hypothesis that these 
place-based contextual and compositional factors are access to care barriers associated with 
higher proportions of late stage CVC diagnosis. We also believe that there are significant 
22 
 
geographic disparities in late stage CVC diagnosis and that these access barriers may help to 
explain why late stage diagnoses rates varies across counties. 
Significance 
Cancer stages represent the extent and spread of the disease. Cervical cancer stage at diagnosis is 
important as it plays a significant role in cervical cancer treatment, prognosis and survival.
1
 
Specifically, late stage (regional and distant) CVC is associated with increased morbidity and 
lower 5-year survival rates.
1
 In fact, the 5-year survival rate for distant cervical cancer is as low 
as 17%, compared to a 5 year survival of 56% for regional cervical cancer and 91.7% for 
localized cervical cancer.
106 
  
With 51% of cervical cancer cases diagnosed at a late stage
3
 it is important to understand the 
factors associated with late stage cervical cancer diagnosis and disparities. Without doing such 
CVC mortality rates will remain high and at a disproportionately higher rate for women in 
various geographical areas and African American and Hispanic women. Currently, cervical 
cancer mortality rates have been consistently higher among Blacks compared to all other race or 
ethnicity groups since 1999.
107 
 According to these national statistics, the overall cervical cancer 
(CVC) mortality rate among African American (AA) women in 2014 was 3.6 per 100,000 
compared to 2.2 per 100,000 among the referent White women.
107 
  However, results of a recent 
study published in January 2017 suggests that after adjusting for hysterectomies the racial gap 
was found to be even wider than previously estimated, with overall CVC mortality rates 
increasing to 10.1per 100,000 among AA women compared to 4.7 per 100,000 among White 
women.
108   
In regard to Hispanic women, the mortality rate is 2.6 per 100,000 women, compared 
to 2.0 per 100,000 among White women .
109  
Similarly, a number of geographic areas are more 
heavily burdened with CVC mortality compared to other areas, with Alabama , Mississippi, 
Arkansas, West Virginia, Tennessee and South Carolina reporting disproportionately higher rates 
of CVC mortality at one of the highest geographical levels (i.e. state) .
110 
Eliminating such 
disparities are among this nation’s top priorities,
36
 as reflected in Healthy People 2020’s 
(HP2020) goal “to achieve health equity, eliminate disparities, and improve the health of all 
groups.”
111
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The proposed study will help support this goal by assessing the spatial distribution of late stage 
CVC diagnosis. The current literature lacks recent surveillance of late stage CVC in the complete 
US and no study has sought to identify concentrated areas of higher than average rates of late 
stage CVC “hotspots” across the US. These hotspots represent geographical disparities and can 
be used to target areas in need of intervention and generate hypotheses regarding significant risk 
factors. Also, by assessing whether geographic hotspots persist over time, we have the potential 
to target worse places and yield greater returns on prevention investments. 
The proposed study will also make significant progress toward HP2020 goal of eliminating 
disparities by investigating the unknown relationships between disparities in stage CVC 
diagnosis and several understudied access to care constructs. To date no study has examined the 
relationships state NP regulations, state cervical cancer screening mandates, PCP shortage areas, 
rates of exempt self-insured employers, or publicly funded health center density have with late 
stage cervical cancer diagnoses. Similarly, no study has assessed whether these access indicators 
are risk factors underscoring significant racial and geographical disparities in stage at CVC 
diagnosis. However, given the substantial variation in the distribution of each of these variables 
across counties and states, and their known associations with CVC screening rates, each likely 
plays an important role in these disparities. Further, given the increased prevalence of ‘self-
insured’ plans in states, which exclude large portions of the insured population from CVC 
screening coverage mandates, we believe self-insured plans may also play an important role in 
stage at diagnosis.
56
   
The results of this study can serve as reliable evidence supporting the need or furtherance of 
policies aiming to reduce the number of late stage CVC diagnoses. Additionally, by assessing 
both independent and interactive associations with stage at CVC diagnosis, we can also 
determine whether the benefits of health policies are greater among more vulnerable population 
groups. Ultimately, the long-term impact will be to inform policies to reduce disparities in late 
stage CVC diagnoses and mortality rates among minority women and women in specific 
geographic regions of the US.   
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Chapter Two: Examining Spatial Clusters of High & Low Proportions of Late Stage 
Cervical Cancer in the U.S.: A Look at Geographic Disparities & Associated Risk Factors 
Introduction  
Prior to the introduction of Pap testing in the early 1950s, cervical cancer (CVC) was the most 
common cancer among women in the United States.
1 
The ability to detect and treat precancerous 
cervical cell changes and early stage cancers through Pap test screening has made cervical cancer 
one of the most preventable of  all cancers.
2 
In fact, due to screening the incidence of cervical 
cancer decreased by more than 50% during 1975- 2014.
3-4
 Since the end of a sharp decline in 
2001, however, CVC incidence rates have remained stable.
4
  
Despite known effectiveness of Pap screening for early detection, recently available data from 
the Surveillance, Epidemiology, and End Results (SEER) registry indicate that 51% of women 
with cervical cancer were diagnosed at a late stage (regional or distant). 
5
 Stage at diagnosis is a 
significant public health concern as it has been found to play a leading role in cervical cancer 
treatment, prognosis and survival.
6
 Specifically, late stage cervical cancer is associated with 
increased morbidity and lower 5-year survival rates.
6
 The 5-year survival rates for distant and 
regional cervical cancer are as low as 17% and 56%, respectively, compared to a 5 year survival 
of 91.7% for localized cervical cancer.
7 
  
Previous epidemiological surveillance using 2001-2003 county-level data from SEER and the 
North American Association of Central Cancer registries indicated that the percent of late stage 
cervical cancer was highest in Iowa, Connecticut, California, New Jersey and Missouri.
8
 A later 
report using 2004-2006 data from cancer registries affiliated with CDC’s National Program of 
Cancer Registries (NPCR) and SEER indicated that late stage CVC incidence rates were highest 
in Arkansas, the District of Columbia, Illinois, Kentucky, Louisiana, Mississippi, Nevada, New 
Mexico, and Oklahoma.
9 
These studies suggest that the incidence and thus the burden of late 
stage CVC varies widely between states in the US. However, little is known about how the 
incidence and burden of late stage CVC differs within specific counties across each of the 
different states.  A few studies have examined the county-level distribution of late-stage CVC 
incidence within a single state,
10-13
 however there is a lack of literature describing the 
distribution of late stage CVC at the county-level across the entire or majority of the US.  
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There are no current studies specifically assessing the spatial clustering of county-level late stage 
CVC rates across the entire US. Identification of county-level clusters of higher than average 
rates of late stage CVC “hotspots” would provide important new information to inform our 
approaches to reducing the burden of late stage CVC.  Examining county as opposed to state-
level data will help us to identify highly burdened places that are potentially masked when using 
aggregated state-level data.  In addition, examining spatial clusters as opposed to simple 
geographic distributions of late stage CVC rates will allow us to generate and test hypotheses 
regarding underlying risk factors that may be common to counties within adjacent states.  
Hotspot analysis is an essential technique used within geographic information system (GIS) 
studies.  However, sophisticated spatial analytic methods such as these have not been frequently 
applied to identify late stage CVC hotspots or generate hypotheses regarding the factors 
underlying late stage diagnoses. This is due in part to a lack of knowledge regarding the utility of 
spatial data, lack of appropriate spatial databases, and previously insufficient spatial analytic 
software.
14 
As a result, previous research on this topic largely underestimates the contribution of 
place; a “ social context deeply connected to larger patterns of social advantage and 
disadvantage.”
15 
To our knowledge, this is the first time this approach has been used to 
understand late stage CVC.  
Using spatial cluster methods, our first aim is to examine geographic disparities in late stage 
CVC diagnosis rates in the US by robustly identifying and characterizing clusters of counties 
considered to be high risk “hotspots” and clusters of counties considered to be low risk 
“coolspots,” during two different time periods, both before and after implementation of the 
preventive services provisions of the Patient Protection and Affordable Care Act (ACA). Our 
secondary aim is to determine whether the hotspots identified in both time periods are associated 
with various contextual and compositional factors. Finally, our third aim is to determine whether 
there are geographic hotspots that persist over both time periods, as these places may represent 
those counties in more urgent need of intervention. It is our hypothesis that there will be spatial 
clusters of higher than expected late stage CVC diagnosis rates in the US and that clusters will 
differ across the two time periods. We also believe these clusters will contain geographic factors 
that can help better explain why late stage CVC varies across counties in the US and how risk 
changes over time.  
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Ultimately, identifying patterns in late stage CVC will allow us to pinpoint the areas in greatest 
need of intervention, to better allocate intervention resources and evaluate performance of 
existing prevention and early detection programs. These findings can also be used to inform 
further research aimed at gaining a better understanding of the underlying causes of late stage 
CVC. Finally, comparing spatial patterns and risk factors pre- and post-ACA implementation 
will allow researchers to generate hypotheses regarding the policy’s impact and effectiveness as 
it relates to cancer prevention and control. 
Methods 
Study Population 
This study includes cervical cancer cases diagnosed during the ten-year period from 2005-2014 
from the United States Cancer Statistics (USCS) database, available at the National Center for 
Health Statistics Research Data Center. The USCS database is a population-based surveillance 
system of cancer registries with data representing 98% of the US population.
16
 This database has 
information on demographics (age, gender, race, and ethnicity), tumor characteristics, and 
geographic location (county of residence) at time of diagnosis.
16
 The confidentiality of data with 
geographic identifiers for county of residence is preserved by restricting access to researchers 
with approved research plans with analyses conducted inside secure federal Research Data 
Centers (RDCs).
16
 There is no access to the Internet from inside the RDC, and all results must be 
reviewed before they can be released from the RDC and published.
16 
All states participate in the USCS registry system, however, five did not allow us to use county 
of residence information (Kansas, Minnesota, Illinois, Michigan, and Missouri).
16
 Therefore, we 
excluded these five states and two additional states, Alaska and Hawaii, because of missing 
contextual data. Our final analysis includes 43 states and their 2,357constituent counties. The 
study sample was further restricted to include all persons having cervical cancer and excluded 
records: when cases were not their primary cancers, when records featured unknown cancer stage 
or unstaged cancer. This restriction resulted in 120,325 individuals living with cervical cancer in 
the US during 2005- 2014. Cases were then divided into two 5-year time periods: those 
diagnosed during 2005-2009 (preACA), and those diagnosed during2010-2014 (post ACA). We 
further categorized cases into late stage (regional and distant) or early stage (localized, including 
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in situ) diagnosis. We then created a county-level late stage diagnosis rate variable for both time 
periods, which was used to address study aim 1. This variable aggregated the total number of late 
stage cases within each county by Federal Information Processing Standard (FIPS) code and 
divided this by the total number of CVC cases. Multiplying by 100 converted these proportions 
into percentages.  
In addition to the USCS’s geographic location, case identification and stage variables, we also 
extracted two additional variables for use in study aim 2, race or ethnicity and age. We created 
six race or ethnicity variables representing the proportion of the population that was White, 
Black, Hispanic, Asian Pacific, American Indian or other. We also created five age variables 
representing the percent of the population that was either less than 40, 40–49, 50–64, 65–74, or 
75 years or older. Additional county-level contextual variables needed for aim 2 were extracted 
from a number of external data sources. Data describing the percentage of the county population 
living in poverty (2005 and 2010), the percentage of individuals under age 65 with no health 
insurance (2005 and 2010) and the percent of individuals unemployed (2005 and 2010) were 
obtained from the U.S. Census Bureau, SAHIE data.17  The proportion of the population age 18-
64 that speaks English poorly (2007-2011) and the percent of population who came to the US 
from a different country in the prior year variables were extracted from the American 
Community Survey.
18 
 Data describing county level population density (i.e. urbanicity) was 
extracted from the Economic Resource Services (ERS) agency.
19
 This measure was calculated by 
dividing the total population in 2010 divided by the total square miles of land area. Higher values 
of this measure indicate more urban places.  
The percent of the state population insured by employers in private self-insured health plans in 
2010 was obtained from the Agency for Healthcare Research and Quality (AHRQ).
20
 Data 
describing the percent of HMO penetration in 2010 was extracted from Kaiser. 
21 
Finally, the 
number of federally qualified health centers (FQHCs) was extracted from the Guttmacher 
Institute’s State- and County-level Family Planning Clinic dataset.
 
 We recoded the FQHC count 
variable into a rate per capita by multiplying each of the counts by 100,000 and dividing the 
product by the total US population in 2005 and 2010.
22
  
Statistical Analysis 
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Using Moran’s I statistics computed using GeoDa software, we robustly identify clusters of  
counties considered to be high risk “hotspots” and clusters of counties considered to be low 
risk “coolspots” across the US during two time periods (pre- and post-ACA 
implementation), aim 1.  Moran’s I statistics are computed based on an underlying assumption 
of constant variance among rates, which can be violated when denominator population sizes vary 
a lot. Therefore, we first assess whether this assumption holds or is violated by developing 
histograms of the distribution of county populations used as the denominators in constructing the 
rates during both time periods and comparing them to a normal curve. Histograms show 
skewness in the distribution of the late stage CVC rates during both time periods, suggesting 
potential for variance instability (Figure 1) due to the fact that the underlying populations at risk 
(all women with CVC) vary in size across counties. Such variance instability in the rates can lead 
to spurious inferences for global and local Moran’s I.
23-24
  To correct for variance instability 
among late stage CVC rates, we use Empirical Bayes (EB) standardization techniques to 
compute global and local spatial autocorrelation statistics. This method is known for adjusting 
these statistics for small sample sizes, reducing the variability of estimates, removing 
erroneously suggested spatial outliers and thus computing robust and reliable clusters.
23-24
 To 
accomplish EB standardization GeoDA computes spatial autocorrelation for transformed 
standardized random variable.
23
 To get this transformed standardized variable GeoDa turns the 
crude rate for each observation into new variable that has a mean of zero and unit variance and 
thus accounts for instability in variance.
23 
Global spatial autocorrelation was determined by performing the EB-adjusted global Moran’s I 
spatial clustering test, which produces a EB Moran’s I coefficient test statistic. Given a 
statistically significant EB Moran’s I coefficient, we reject the null hypothesis of spatial 
randomness and conclude that there is global clustering in the patterns of late stage CVC rates 
across counties. After confirming that there was global clustering we calculated EB-adjusted 
Local Indicators of Spatial Association (LISA) to pinpoint the specific locations of the 
statistically significant clusters within both time periods. At significance level <0.05, the EB 
LISA test first calculates a test statistic for each county representing whether the county has a 
statistically significant higher or lower than the national average rate of late stage CVC.  
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To determine statistical significance of EB LISA test statistics, GeoDA uses a permutations 
approach called bootstrapping. This approach compares the actual correlation between late stage 
CVC measures among a county and its neighbors with 1000 or more correlations between the 
county in question and groups of randomly chosen neighbors. Queen contingency matrix weights 
are used to define neighboring counties. A statistical distribution is generated by the more than 
1000 permuted repetitions with the random neighbors and is assessed to determine where along 
the distribution the actual correlation falls. If the actual correlation with neighbors falls in the tail 
of the distribution then we reject the null hypothesis of local spatial randomness and conclude 
that the county’s correlation with actual neighbors is statistically significantly unlikely to have 
occurred by chance. This assessment is repeated independently for each county in the dataset, 
and the collection of test statistic findings for all counties are mapped together in a single LISA 
clustering map. 
Using statistically significant EB LISA test statistics, four distinct cluster types are formed in 
both time periods:  high-high, low-low, low-high and high-low. High-high clusters include 
counties with higher than average rates surrounded by other counties with higher than average 
rates. Similarly, low-low clusters include counties with lower than average rates surrounded by 
other counties with lower than average rates. Low-high and high-low clusters are developed in a 
similar fashion. Among all cluster types, those that were statistically significant were presented 
in two separate maps, one for each time period, using QGIS software.  To represent the entire 
cluster both maps included the counties at the center of the cluster and their surrounding 
neighbors. To determine whether the hotspot clusters identified during both time periods 
were associated with various contextual and compositional factors, aim 2, we employed two 
sets of independent sample t-tests in SAS version 9.0. Specifically, for both time periods, we 
grouped all high-high clusters together and all low-low clusters together and treated them as two 
independent groups. We then tested for statistically significant differences in the means of the 
underlying biological and contextual factors between the two cluster groups.  
Finally, to determine whether there were geographic hotspots that persisted over both time 
periods, aim 3, we developed a colocation map. To develop the colocation map we grouped 
counties into three categories: those that belonged to significant hotspot clusters in both periods 
(persistently hotspots), those that did not belong to significant hotspot clusters in either period 
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(persistently non-hotspots), and those that transitioned into or out of a hotspot clusters 
(transitional hotspots). The coincidence of these three categories across the two time periods was 
then mapped using QGIS software.  
Results 
LISA Cluster and Persistent Hotspot Results (Figures 1-3) 
Empirical Bayes (EB) adjusted Global Moran’s I tests indicate that there is significant positive 
spatial autocorrelation among the proportions of late stage CVC during both time periods, 
(significance level α=0.05). Thus, for both time periods, we reject the null hypothesis of spatial 
randomness and conclude that the proportions of late stage CVC across neighboring counties 
were too similar in some local areas to have occurred by chance.  
Using EB adjusted Local Moran’s I tests, we further determined which local areas were 
statistically significantly spatially correlated with one another with regards to late stage CVC 
proportions- location of local clusters. During both time periods, we found several statistically 
significant local high and low rate cluster centers. High-rate clusters centers are areas where 
counties and their neighbors have statistically significantly higher proportions of late stage CVC 
than would be observed by chance, using a 5% level of significance. These clusters will be 
referred to as “hotspots” going forward. Low-rate clusters centers are areas where counties and 
their neighbors have statistically significantly lower proportions of late stage CVC than would be 
observed by chance, using a 5% level of significance. These clusters will be referred to as 
“coolspots” going forward.  
During 2005-2009, we found 111 statistically significant hotspots (colored red) and 77 
statistically significant coolspots (colored blue). Hotspots were observed in 24 of 43 states but 
were most apparent throughout the Eastern and Southern regions of the US, as well as California, 
Colorado, Connecticut, Massachusetts and Wyoming. Coolspots were observed in 23 of 43 states 
but were most apparent throughout the Eastern and Southern regions of the US, as well as 
Oregon, Florida, Georgia and Oklahoma. (Figure 1)   
During 2010-2014, we found 89 statistically significant hotspots (colored red) and 93 statistically 
significant coolspots (colored blue). Hotspots were observed in 19 of 43 states but were most 
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apparent in Florida, Pennsylvania, Oklahoma, New York and other states within the Southern 
and Eastern regions of the US. Coolspots were observed in 26 of 43 states but were most 
apparent in Georgia, Arizona, Utah, Oregon, Washington and other states within the Eastern 
region of the US. (Figure 2) 
Over time the number of statistically significant hotspot clusters decreased while the number of 
statistically significant coolspot clusters increased. However, colocation mapping shows that 
there were 56 hotspot clusters that persisted overtime. Persistent hotspot clusters were observed 
in 13 of 43 states and were most apparent in California, Louisiana, Alabama and Georgia. 
(Figure 3) 
Comparison of High and Low Rate Clusters: T-test Results (Table 1-2) 
To determine what factors were associated with hotspot clusters, we tested for significant 
differences in the means of the underlying compositional and contextual between the hotspot and 
coolspot clusters observed in both time periods. During the early period, we found that hotspot 
clusters had a statistically significantly higher proportion of women who were White, Asian and 
individuals less than age 50 among the CVC sample population, compared to coolspot clusters. 
Hotspot clusters in the early period also had a statistically significantly higher proportion of 
counties that were underserved by a primary care provider, compared to coolspot clusters. In 
addition, compared to coolspot clusters, hotspot clusters had statistically significantly lower 
proportions of African American women among the CVC sample population, and lower 
proportions of unemployed persons and 18-64 year olds that spoke English poorly in the general 
population. Finally, we found that hotspot clusters in the early period had a statistically 
significantly lower proportion of HMO penetration. (Table 1) 
 When comparing hotspot and coolspot clusters observed during the later period we found 
drastically different associations than what was found when comparing cluster groups observed 
during the early period. During the later period, we found that hotspot clusters had a statistically 
significantly higher proportion of people that were in poverty, unemployed, and in self-insured 
insurance plans that were exempt from state regulations. Compared to coolspot clusters, hotspot 
clusters also had a statistically significantly higher proportion of African American women in the 
CVC sample women and a higher proportion of counties that were underserved by a primary 
44 
 
care provider. We also found that hotspot clusters had a statistically significantly lower 
proportion of White and Asian women as well as individuals less than age 50 in the CVC sample 
population, compared to coolspot clusters. During the later period, the percent of HMO 
penetration was also statistically significantly lower in hotspot clusters compared to coolspot 
clusters. (Table 2) 
Discussion 
Although the number of CVC cases has decreased over time, the proportion of CVC cases 
diagnosed at a late stage has increased from 47% to 54% overall. This highlights the need to 
identify former, existing and persisting clusters of high proportions of late stage CVC and to 
determine what factors are associated with these clusters. The results of this study are essential 
for pinpointing areas in need of intervention and generating hypothesis regarding the causes of 
late stage CVC.  
The LISA clustering method is a sophisticated spatial method used to identify areas in need of 
intervention by pinpointing areas of local clustering of rates. This method has been used to 
identify high risk areas in a number of studies
25-26
 However, this method assumes constant 
variance in the rates across the areas, which was not the case for our study measure. This was 
due to there being small counts in both the numerator (CVC cases diagnosed at a late stage) and 
denominator (all CVC cases) of the proportion of late stage CVC variable. To ensure that this did 
not bias the clustering results we employed a more robust LISA technique called Empirical 
Bayes (EB) adjusted LISA. This method has never been used to identify clusters of high 
proportions of late stage CVC. However, there were significant differences in the location of 
clusters when EB and traditional LISA methods were used, which emphasize the importance of 
adjusting for variance instability in order to properly identify clusters. For example, using 
traditional LISA methods there were hotspot clusters observed in Montana and North Dakota 
during the early period (Figure 4). However, using EB adjusted LISA methods there were no 
hotspot clusters observed in either Montana or North Dakota during the early period. (Figure 1) 
This suggests that the late stage CVC LISA results were overestimated when traditional LISA 
techniques were used. Therefore, we take clusters observed using EB adjusted LISA to be most 
reliable and robust.  
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Using EB adjusted LISA, we found that there were substantial changes in the number and 
distribution of clusters over time and that the distribution of hotspots were not consistent with the 
state-level burden of late stage CVC identified in previous literature.  Maps of EB adjusted LISA 
clusters show that the overall number of hotspots decreased from 111 to 89 over time while the 
number of coolspots increased from 77 to 93 over time. Maps also show that hotspots observed 
in Massachusetts, Connecticut, Wyoming and Colorado during the early period were no longer 
observed in the later period. We also found that over time local areas in both Utah and Arizona 
developed coolspots. On the other hand, some places such as Florida, Oklahoma and 
Pennsylvania developed hotspots over time. There are also areas in California, Louisiana, 
Alabama and Georgia that presented hotspots during both time periods.   
There are several implications that can be drawn from the changes in the distribution of clusters 
over time. Local clustering of proportions into significant hot and coolspots during both the early 
and late period suggests that there were and still are geographic disparities in the proportion of 
late stage CVC across counties and states. It can also be implied that places that developed 
coolspots or lost hotspots over time may have implemented effective CVC interventions or early 
detection programs that worked to attenuate the geographic disparities that were once present. 
On the other hand, it can be implied that places with newly developed hotspots likely represent 
those places where there was a release in the pent-up demand for CVC screening services 
overtime. During the early period (2005-2009), there was a pent-up demand for CVC screening 
across the US due to a number of women having limited or no health insurance coverage. 
However, during the later period (2010-2014), millions gained access to CVC screening services 
via Affordable Care Act (ACA) provisions that mandated full coverage for preventative services 
in 2010
27
 and expanded Medicaid in 2014.
28
 Thus, newly developed hotspots are likely driven by 
a higher number of women being screened for CVC and in turn a higher number of diagnoses 
overtime. Lastly, places displaying persist hotspots overtime such as those observed in 
California, Texas and Southeast regions of the US represent those places in greatest need of 
interventions.  
 Implications can also be drawn from the comparisons of the differences in the means of 
contextual and compositional variables between hotspots and coolspots. The early period t-test 
results indicate that the percent of sample women with CVC who were Asian and White and 
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women under the age of 50 was significantly higher in hotspot clusters compared to coolspot 
clusters.  However, this association changed over time. During the later period, the percent of 
sample women with CVC who were African American and women over the age of 50 became 
significantly higher and the percent of sample women with CVC who were White or Asian 
became significantly lower in hotspot clusters compared to coolspot clusters. These findings are 
consistent with the current literature which suggests that African Americans, Hispanics and 
women over 50 are now among those disproportionately burdened by late stage CVC.
29-30
 
Additional research is needed to understand why African American women and women over 50 
are at greatest risk for late stage CVC. Similarly, additional research is also needed to understand 
what preventive programs, policies of behavior changes are associated with decreased risk of late 
stage CVC among Asian and White women over time. This information could be useful for 
developing intervention strategies among other race or ethnic populations.   
In addition to the associated compositional factors, we also found that several factors that were 
not associated with hotspot clusters in the early period showed a significant relationship with 
hotspot clusters over time. Specifically, we found that the percent uninsured, unemployed, in 
poverty and insured by employers in self-insured plans exempt from state regulations became 
statistically significantly higher in hotspot clusters compared to coolspot clusters over time. 
These results suggest that overtime the proportion of late stage CVC became more strongly 
influenced by barriers to access to care, as a higher percent of unemployed, uninsured, those in 
poverty, individuals insured by employers in self-insured plans exempt from state regulations, 
and individuals underserved by a primary care provider, each represent access to care barriers.  
Although coverage and cost sharing provisions were implemented under ACA between 2012-
2014, we were not surprised to find that several access to care barriers were associated with 
higher proportions of late stage CVC during the 2010-2014 time period. The ACA has made 
significant strides toward improving access to CVC screening, however, it has not eliminated 
access barriers for all women. Following the implementation of the ACA, there were still 44.4 
million individuals left uninsured and thus potentially facing issues regarding access and 
affordability of care.
31
 Furthermore, the shortage of primary care physicians (PCP) is projected 
to increase to as many as 49,300 PCPs by the year 2030.
32 
This presents a potential barrier to 
access to healthcare for women in the US, including those with insurance, as the US is already 
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experiencing a PCP shortage. Together these unresolved issues of affordability and availability 
of care can significantly shape access to CVC screening and thus stage at diagnosis. This 
demonstrates the need to further develop strategies to combat the issue of access to care, as the 
protective effects of the ACA are limited.  
Together these results demonstrate that there are both geographic and demographic disparities in 
late stage CVC. Study results also suggest that late stage cervical cancer incidence and 
geographic disparities are likely influenced by county- and state-level factors, as clusters vary 
across counties and states. Results further demonstrate that the county-level factors associated 
with the current burden of late stage CVC are all indicators of access to care. These indicators 
include employment status, insurance coverage, poverty level, primary care shortage, HMO 
penetration and insurance plan exemptions from state-based health regulations. Advanced 
inferential statistics are needed to further investigate the relationships between various county- 
and state-level access to care barriers and late stage CVC incidence and disparities. More 
specifically, these relationships should be further investigated using mixed modeling methods 
which consider the hierarchical structure of the data. Using this approach the researcher can 
simultaneously examine the effects of county and state level variables and the interactions within 
and between them.  
Without further investigation into these relationships the overall proportion of late stage CVC in 
the US will remain high and at a disproportionately higher rate among African American and 
Hispanic women and women in the identified hotspot clusters across the US. Stage at diagnosis 
is of significant public health concern as it plays a leading role in cervical cancer treatment, 
prognosis and survival.
6
 In fact, the 5-year survival rate for distant and regional cervical cancer is 
as low as 17% and 56% respectively, compared to a 5 year survival of 91.7% for localized 
cervical cancer.
7 
The results of the current study will help to reduce the number of late CVC 
cases and associated mortality by informing further research aiming to gain a better 
understanding of the underlying causes of late stage CVC. This study also pinpoints areas in 
greatest need of late stage CVC interventions, by identifying geographic hotspots that persist 
over both time periods, as seen in states including California, Louisiana, Alabama and Georgia.   
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Table 1 : T-test  Comparing the Mean of Contextual and Demographic Variables Between EB adjusted Hotspot and 
Coolspot Clusters during 2005-2009 
 Variable 
Description 
Mean in Hotspots 
(N= 385) 
Mean in Coolspots 
(N=339) 
P value, for t-test 
of differences in 
means 
Contextual Characteristics of Counties of Residence 
Under05 Percent underserved 
by a Primary Care 
Provider, 2005  
 
46.9216 45.0018 <.0001 
Xpoorne Poor English 
Speaking among 18-
64 year old 
(proportion) 
 
0.1291 0.1448  0.0347 
Xpov05 Percent of people of 
all Ages in Poverty 
for Income year 2005  
 
3.58 3.36  0.5678 
Xself06 Percent insured by 
Employers in Self-
Insured Plans 
Exempt from State 
Regulations 2006 
 
26.78 27.53 0.5979 
Xune05 Percent Unemployed 
2005 
 
9.32 12.01 0.0075 
Xhmo05 Percent HMO 
Penetration  2005 
 
5.0935 5.7215  <.0001 
Xuni05 Percent of total pop 
<65 uninsured  2005 
 
9.38 10.72  0.1462 
MovedCe Percent of population 
that moved from  
different country last 
year 
 
0.3209 0.2984 0.0030 
Pop05/Land Population Density 
2005 (urbanicity) 
349.4 228.5  0.1051 
Sample Population Demographic Characteristics 
Agels50 Percent under age 50 
 
55.93 50.14 0.0003 
Aian Percent American 
Indian  
 
9.74 9.62  0.2675 
Black Percent Black  
 
12.16 17.80   0.0005 
Asian Percent Asian  
 
1.58 0.751  0.0025 
White Percent White  
 
76.84 71.81  0.0082 
Hispanic Percent Hispanic  2.29 2.62  0.4992 
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Table 2 :T-test  Comparing the Mean of Contextual and Demographic Variables Between EB adjusted Hotspot and 
Coolspot Clusters during 2010-2014 
 Variable 
Description 
Mean in Hotspots 
(N= 350) 
Mean in 
Coolspots 
(N=335) 
P value, for t-test 
of differences in 
means 
Contextual Characteristics of Counties of Residence 
Under12 Percent underserved 
by a Primary Care 
Provider, 2012  
 
13.0312 10.9681 <.0001 
Xpoornl Poor English 
Speaking among 18-
64 year old 
(proportion)  
 
0.0191 0.0216  0.5614 
Xpov10 Percent of people of 
all Ages in Poverty 
for Income year 2010 
 
18.61 14.50   <.0001 
Xself13 Percent insured by 
Employers in Self-
Insured Plans 
Exempt from State 
Regulations 2013 
 
62.3106 60.5290  0.0003 
Xune10 Percent Unemployed 
2010 
 
10.4811 9.2087  <.0001 
Xhmo10 Percent HMO 
Penetration  2010 
 
13.5544 16.5991  <.0001 
Xuni10 Percent of total pop 
<65 uninsured  2010 
 
20.1954 17.3681  <.0001 
MovedCe Percent of the 
population that 
moved from a 
different country 
 
0.297 0.379 0.0098 
Pop10/Land Population Density 
2010(urbanicity) 
451.3 336.7 0.5989 
Sample Population Demographic Characteristics 
Agels50 Percent under age 50 45.55 53.51 <.0001 
Aian Percent American 
Indian  
 
1.77 2.67  0.2345 
Black Percent Black  16.78 8.38  <.0001 
Asian Percent Asian  1.12 1.91  0.0150 
White Percent White  72.59 76.76  0.0394 
Hispanic Percent Hispanic  7.04 9.45  0.0504 
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Chapter Three: Availability and Affordability of Care Influencing Late Stage Cervical 
Cancer Diagnoses and Disparities in the U.S. 
Introduction 
Recent data from the Surveillance, Epidemiology, and End Results (SEER) registry indicate that 
51% of women with cervical cancer (CVC) were diagnosed at a late stage (regional or distant),
1
 
an outcome associated with increased morbidity and mortality.
2
 Epidemiological surveillance 
suggests that women who are over the age of 50,
3
 African American,
3-4
 Hispanic,
3 
and those 
residing in specific geographic regions of the US are more likely to have CVC diagnosed at a 
late stage.
3
 Foreign born women,
5
 women without health insurance,
6
 and women with lower 
incomes are also more likely to report late stage CVC diagnosis.
7
 
 
 Studies have shown that women who are screened for cervical cancer (CVC) are significantly 
less likely to be diagnosed at a late stage.
8-10 
In fact, recent studies suggest that the most 
significant predictor of stage at CVC diagnosis is current screening defined as having a Pap 
smear within the past three years.
 11-13
 
 
Utilization of cervical cancer screening is largely 
attributed to access to care
11-13
 
 
and there are a number of identified barriers women face in 
obtaining this service,
14-22
 with some women experiencing greater challenges than others.
23 
Studies suggest that women experience unequal access to CVC screening due to factors related 
to: insurance and employment status, income, distance to nearest primary care clinics, schedule 
availability, transportation costs and lack of a usual source of health care.
14-22
  
The implementation of the Patient Protection and Affordable Care Act (ACA) has helped to 
mitigate the issue of poor access to CVC screening by expanding access to health insurance to 
more than 20 million individuals in the US.
24
 In addition, the ACA mandated that all health 
insurance plans were required to cover CVC screening in full, without cost-sharing (copayments 
or out of pocket costs) to insureds.  As a result, the ACA has been shown to be associated with 
increased CVC screening rates and early stage diagnoses.
25-26
 A 2016 study reported that the 
ACA was associated with a 21.2% increase in early stage (stage I) cervical cancer diagnoses 
among cancer patients aged 19-25 years.
25 
A systematic review of 14 studies in 2017 also found 
that the ACA had a significant impact on cancer screening, including Pap tests. 
26
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Although the ACA has made significant strides toward improving access to CVC screening, it 
has not eliminated access barriers for all women. Following the implementation of the ACA, 
there were still 44.4 million individuals left uninsured and thus potentially facing issues 
regarding access and affordability of care.
27
 Furthermore, the shortage of primary care physicians 
(PCPs) is projected to increase  as demand outpaces supply.
28 
 This presents a potential barrier to 
access for women, including those with insurance, as the US is already experiencing a PCP 
shortage.
29
 Together these unresolved issues of affordability and availability of care can 
significantly shape access to CVC screening and thus stage at diagnosis. The current literature is 
in need of data describing how PCP shortage and factors associated with affordability of care for 
uninsured women are associated with stage at CVC diagnosis.  
Availability – Primary Care Physician Shortage  
Over time, data have consistently demonstrated the unmet need for additional primary care 
physicians in the US.  According to the Association of American Medical Colleges (AAMC), 
there were an estimated 91.7 primary care physicians per 100,000 people in the US in 2016.
30
 
This translates to a total supply of approximately 296,353 primary care physicians.
30  
Based on 
the current supply, there were 7,176 designated primary care health professional shortage areas 
(areas with <1 primary care physician per 3,500 people) in the US in 2017.
31
 Current Health 
Resources and Services Administration (HRSA) reports project that this shortage will be 
exacerbated as the population grows and as expanded insurance coverage provisions of the ACA 
take effect.
28
 In fact, the PCP shortage is expected to increase to between 14,800 and 49,300 
primary care physicians by year 2030.
28
  
The primary care physician shortage is of grave public health significance as leaving individuals 
without readily available care can impact a wide range of health outcomes. Research suggests 
that for every additional PCP per 10,000 there is a 5.3% decrease in all-cause mortality per 
year.
31 
Research also suggests that the physician shortage is a key determinant of disparities in 
access to care. With over 100 million Americans medically underserved,
32
 these individuals 
report a lower quality of health services and are less likely to receive  routine medical 
procedures, including screening.
33
 In fact, compared to women living in areas of higher 
physician density (500 or more office-based primary care physicians per 100,000), women who 
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live in areas of lower physician density (<100 office-based primary care physicians per 100,000 
women) were significantly less likely to receive a Pap test in the past 3 years.
34-35  
Affordability- Community Health Centers & Publicly-Funded Clinics 
Community health centers (CHC) were developed with the specific goal of providing high 
quality and comprehensive primary care to medically underserved populations, regardless of 
their ability to pay.
36-37 
Both CHC and other publicly-funded clinics provide free or low-cost 
services through a number of publicly funded programs including Title X family planning grants 
and the Medicaid program.
36 
Grantee sites include federally qualified health centers (FQHC), 
Planned Parenthood affiliates, public health departments, hospitals and other health care 
providers. These sites provide a wide range of primary and preventive services, including 
cervical cancer screening, to individuals who are disproportionately uninsured, low income, and 
racial or ethnic minorities.
38
  
Community health centers and other publicly funded clinics are not evenly distributed across the 
US.
39 
 For example, some states have as many as 176 community health centers while others 
have a few as four.
36
 The number of active community health centers is essential to public health 
as they play a critical role in providing access to care and reducing health disparities among their 
patient population of nearly 27 million.
36
 Research further indicates that Title X-funded centers 
alone (including both CHC and publicly-funded clinics) were responsible for providing 
affordable CVC screening to more than 743,000 female clients across 3,900 Title X-funded 
health clinics in 2015.
40 
Data also suggest that community health centers, irrespective of funding 
source, have been successful in expanding access to CVC screening and reducing related health 
disparities among their socioeconomically and racially diverse patient populations. In fact, health 
centers have provided 4% more Pap smear services to women in need of these services over the 
last 3 years compared to other health facilities.
36
 Data also suggest that 92% of Hispanic women 
in need of a Pap test at health centers actually received these services compared to only 69% of 
Hispanic women in need of these services nationally who actually received them.
36
 Similarly, 
89% of African American women in need of a Pap test at health centers actually received these 
services compared to only 75% of African American women in need of these services nationally 
who actually received them.
36
  Thus, these centers and clinics appear to serve a disproportionate 
share of the minority women in need. 
61 
 
The purpose of this paper is to determine whether late stage diagnosis of CVC is associated with 
PCP shortage and the number of CHCs and other publicly funded clinics that provide services at 
low or no cost per 100,000 people. Considering that minority communities are disproportionately 
represented among medically underserved populations and that publicly funded clinics 
predominately serve minority populations, we also aim to determine whether the relationships 
between   the number of Planned Parenthood clinics per 100,000 people and CVC stage at 
diagnosis and PCP shortages and stage at CVC diagnosis  differ by race or ethnicity. It is our 
hypothesis that these multilevel factors act as access to care barriers associated with higher odds 
of late stage CVC diagnosis. We also believe that there are significant racial disparities in late 
stage CVC diagnosis and that these access barriers may help to explain them.  Although 
assessing the influence of the interaction between race or ethnicity and FQHCs would have also 
provided useful information, data describing the influence of FHQCs on racial disparities in 
CVC outcomes already exists. However, to our knowledge there are no studies that have 
assessed the relationship between racial disparities in stage at CVC diagnosis and Planned 
Parenthood clinics. Thus, we contribute to the current literature by investigating this unexplored 
relationship along with others. This study can provide evidence informing health policies aiming 
to reduce racial disparities in stage at CVC diagnosis by addressing the number of PCPs and 
publicly funded clinics in minority communities across the US. 
Methods 
Conceptual Model  
The literature indicates that many health outcomes such as access to screening and subsequent 
disparities in stage at diagnosis are influenced by complex and interacting social, environmental 
and behavioral processes that occur at varying geographical and socioecological scales.
41 
Several 
researchers have reported that despite efforts to change, many health disparity studies have 
continued to focus solely on individual level explanations and have failed to include explanations 
of the spatial processes and pathways to health outcomes.
42-44
 However, failing to account for 
multilevel factors and spatial processes, when they present, has been found to significantly bias 
regression estimates.
45
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To address the concerns raised in the recent literature and achieve unbiased estimates, we 
developed a multilevel conceptual model for understanding access to CVC screening and late 
stage CVC outcomes by drawing from the current literature and both Aday and Andersen’s 1974 
Access Framework
46
 and Penchansky and Thomas’s 1981 Theory of Access.
47 
This hybrid model 
describes the influence and cross-level interactions among two levels. Level 1 includes 
individual factors that vary from person to person. The individual factors included in the model 
were mostly selected to represent what Aday and Andersen define as predisposing and 
enabling/disabling characteristics of the population at risk. Unfortunately, enabling/disabling 
characteristics such as information regarding personal income or insurance status is not available 
for the CVC cancer population. Thus, we only include the predisposing characteristics age and 
race or ethnicity. Level 2 includes healthcare market factors which vary across counties. The 
health market factors included were selected to reflect what Penchansky and Thomas define as 
availability, affordably and accessibility factors. Factors representing the affordability of care 
include CHC and publicly funded clinics, persistent poverty and percent uninsured. Factors 
representing the availability of care include PCP shortages and English language proficiency. 
Finally, accessibility is represented by the population density variable which is a measure of 
urbanicity. Each of the variables in the model have been found or are hypothesized to influence 
stage at CVC diagnosis. However, more aspects are listed than can be modeled using currently 
available data or computing power. We describe the specific variables used and a rationale for 
using them below. 
Table 1: Descriptive of Study Variables 
Variables  Description of Measures & 
Source 
Rationale 
Dependent Person-Level Variable 
Late Stage CVC Diagnosis CVC cases diagnosed during 
2010-2014 were categorized into 
late stage (regional and distant) or 
early stage (localized, including 
in situ diagnosis. Created 
dichotomous variable for late 
stage diagnosis Y/N. (USCS)
48 
Early detection and treatment of 
cervical cancer can significantly 
reduce the probability of cancer 
mortality.
2
 However, stage at 
diagnosis is associated with a 
number of factors ,with barriers 
related to utilization of timely 
cancer screening being among top 
predictors.
11-13
 
Independent Person-Level Variables (Level 1) 
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Race  or Ethnicity 
 
 
 
 
 
 
 
 
Age 
Race or ethnicity categorized into 
6  groups (non-Hispanic White, 
non-Hispanic Black, Hispanic, 
Asian and American Indian, and 
other) with non-Hispanic White 
as the reference group. (USCS)
48 
 
 
Age categorized into two groups: 
less than 50 (reference) and 50 
and older. (USCS)
48 
African American and Hispanic 
women have the highest incidence 
of CVC, are significantly less likely 
to be screened for CVC and are 
more likely to be diagnosed at a late 
stage, compared to all other races.
3-
4,49
 
 
Women over the age of 50 are 
significantly more likely to be 
diagnosed at a late stage.
3
 
Independent County-Level Variables (Level 2) 
Percent Uninsured 
 
 
 
 
 
 
 
Moved From Different Country 
 
 
 
 
Urbanicity 
 
 
 
Percent Poverty 
 
 
 
HMO Penetration  
 
 
 
 
Federally Qualified Health Centers 
 
 
 
Planned Parenthood Clinics 
 
 
 
 
 
 
 
 
 
Percentage of individuals under 
age 65 with no health insurance in 
2010. (U.S. Census Bureau, 
SAHIE data)
50 
 
 
 
 
Percent of population who came 
to the U.S. from a different 
country last year 2007-2011. 
(ACS)
52 
 
Population density in 2010 
(ERS)
55 
 
 
 
 
 
County level variable of percent 
of individuals of all ages in 
poverty in 2010. (ACS)
52 
County-level variable of percent 
HMO penetration. (Kaiser) 
 
The county number of FQHCs  
per 100,000 people in 2013. 
(Guttmacher Institute)
56
* 
The county number of Planned 
Parenthoods per 100,000 people 
in 2013. (Guttmacher Institute)
56
* 
*Multiplied each of the counts by 
100,000 and divided the product 
by the total U.S. population for 
each county in 2010 to get count 
Health insurance status and type  
are significant predictor of both late 
stage CVC and access to CVC 
screening.
6
 We control for health 
insurance coverage for women up 
until age 65, the cut off age for 
recommended CVC screening.
51
 
 
Recent immigration status is a 
significant barriers to CVC 
screening among Hispanic 
populations.
53-54
 
 
Women in rural areas and those in 
economically deprived non-rural 
communities are less likely to 
screen for CVC and report lower 
screening rates compared to women 
in urban and suburban areas.
 17,53 
 
Women with lower income and are 
more likely to be diagnosed at a late 
stage.
7
 
 
Health insurance status and type  
are significant predictor of both late 
stage CVC and access to CVC 
screening.
6
  
 
The primary interest of this paper is 
the influence of CHC, publicly 
funded health centers and PCP 
shortage on both stage at CVC 
diagnosis and racial disparities in 
CVC diagnosis, which has never 
been explored. As described above, 
we believe the heterogeneity in 
these variables across counties 
plays a huge role in access to CVC 
screening and pathway to late stage 
CVC diagnosis and disparities.  
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PCP Shortage 
 
 
per 100,000 people. 
Number of full-time equivalent 
(FTE) PCPs needed in the Health 
Professional Shortage Area 
(HPSA) so that it will achieve the 
population to PCP  target ratio 
(3,500 to 1) (HRSA)
57
 The PCP 
shortage variable does not take 
into account the need for other 
providers in the primary care 
workforce such as nurse 
practitioners and  physician 
assistants.
  
 
 
 
 
 
Study Population 
This study examined all primary cervical cancer cases diagnosed during the years of 2010-2014, 
from the United States Cancer Statistics (USCS) database, available at the National Center for 
Health Statistics Research Data Center.
48 
 The USCS database collects information on cancer 
incidence and survival from registries that have high quality data that represent 98% of the US 
population.
48
 Included in the database is information on demographics (age, gender, race, and 
ethnicity), tumor characteristics, and geographic location (county of residence) at time of 
diagnosis.
48
 Only those researchers with approved research plans are granted access to the 
database and all analyses must be conducted inside secure Federal Research Data Centers 
(RDCs).   
All states participate in USCS registry data system database. However, five states (Kansas, 
Minnesota, Illinois, Michigan and Missouri) do not allow use of county of residence information 
for researchers in the RDC.
48
 We excluded these five states and two additional states, Alaska and 
Hawaii, because of missing contextual data. The study sample was further restricted to include 
all persons having cervical cancer and excluded records: when cases were not their primary 
cancers and when records featured unknown cancer stage or unstaged cancer. These restrictions 
resulted in 59,360 individuals with cervical cancer living in 43 states during 2010 -2014.  
We examined cases within the database during 2010-2014 because this time period represents 
the beginning of a significant time period in the US, with the implementation of the Affordable 
Care Act (ACA).  Beginning in 2010, provisions under the ACA resulted in thousands of 
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individuals with pre-existing conditions obtaining health insurance through a national high-risk 
pool program.
58
 Provisions under the ACA also resulted in millions of women gaining full 
coverage for CVC screening via provisions mandating coverage of preventive services without 
cost-sharing beginning in 2012
24
 and millions of people obtaining health insurance via Medicaid 
expansion and individual health insurance marketplace subsidies beginning in 2014
59
. Therefore, 
we expect that access to care barriers and their relationships with health outcomes during the 
time period 2010-2014 will considerably be different than those observed during any time period 
prior to 2010.  
Measures 
Cervical cancer cases were categorized into late stage (regional and distant) or early stage 
(localized, including in situ) diagnoses. We then created a dichotomous person-level late stage 
cervical cancer outcome variable (yes/no). In regard to study predictors, we also extracted two 
person-level covariates from the USCS databases
48
, race or ethnicity and age. We created the 
race or ethnicity variable by combining USCS’s race and Hispanic variables. Race or ethnicity is 
a recoded variable categorized into six race or ethnicity groups: non-Hispanic White, non-
Hispanic Black, Hispanic, Asian Pacific, American Indian and other. The age variable is 
categorized into two groups: less than 50 (reference) and 50 and older.  
County level variables were extracted from a number of external data sources. Data describing 
the percentage of individuals under age 65 with no health insurance in 2010 were obtained from 
the U.S. Census Bureau, SAHIE data.
50
 The percent of individuals of all ages in poverty in 2010 
and the proportion of population who came to the US from a different country in the prior year 
(2007-2011) variables were obtained from the American Community Survey (ACS).
52 
Data 
describing the percent of HMO penetration in 2010 was extracted from Kaiser.  Data describing 
the population density (i.e. urbanicity) in 2010 were extracted from the Economic Resource 
Services (ERS) agency.
55
This measure was calculated by dividing the total population in 2010 
divided by the total square miles of land area. Higher values of this measure indicate more urban 
places.  
The county level primary care physician (PCP) shortage variable which represents number of 
full-time equivalent (FTE) PCPs needed in the Health Professional Shortage Area (HPSA) so 
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that it will achieve the population to PCP target ratio (3,500 to 1), was obtained from HRSA 
database.
57 
The PCP shortage variable does not take into account the need for other providers in 
the primary care workforce such as nurse practitioners and physician assistants. The number of 
FQHCs and Planned Parenthood clinics were obtained from Guttmacher Institute’s 
Contraceptive Needs and Services 2013 data report.
56
 We recoded each of the three health center 
count variables into counts per 100,000 people by multiplying each of the counts by 100,000 and 
dividing the product by the total US population for each county in 2010. The primary interest of 
this paper is the influence of CHCs, publicly funded clinics and PCP shortages on both stage at 
CVC diagnosis and racial disparities in CVC diagnosis, which has never been explored. As 
described above, we believe the heterogeneity in these variables across counties plays a huge 
role in access to CVC screening and pathways to late stage CVC diagnoses and disparities. 
Statistical Analysis 
To examine predictors of late stage cervical cancer diagnosis we estimated two multilevel 
models using data from person and county levels. With persons nested within counties, we 
specifically used Generalized Linear Mixed Model (GzLMM) to fit two separate two-level 
random intercept logit model. Both models included several person and county level covariates 
and one cross level interaction. The models differed only in the cross-level interaction included; 
all other variables were the same. The first model included an interaction between race or 
ethnicity and PCP shortage and the second model included the interaction between race or 
ethnicity and the number of Planned Parenthood clinics per 100,000 people. Final random and 
fixed parameter estimates were calculated using Full Maximum Likelihood (FML) estimation in 
SAS 9.2 statistical software. We selected the multilevel model framework because it has been 
found to be the most efficient model for assessing correlated data or predictors at various levels 
simultaneously. This approach was also selected because it controls for omitted county-level 
effects that might bias the disparity estimates.
45
 The results of these models provide us with 
estimates of the probability of late stage CVC given various access indicators, answering the 
following research questions: 
 Are lower numbers of FQHCs per 100,000 people associated with increased odds of late 
stage for cervical cancer among women in the US, controlling for other variables? 
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 Does the relationship between PCP shortage and stage at cervical cancer diagnosis differ 
by race or ethnicity, controlling for other variables? 
 Does the relationship between the number of Planned Parenthoods clinics per 100,000 
people and stage at cervical cancer diagnosis differ by race or ethnicity, controlling for 
other variables? 
 Are women of a specific race or ethnicity or age more likely to be diagnosed at a late 
stage for cervical cancer, controlling for other variables? 
 Are higher area-level poverty, uninsured and HMO penetration rates associated with 
higher odds of late stage CVC among women in the US, controlling for other variables? 
 Is urbanicity associated with the odds of late stage CVC among women in the US, 
controlling for other variables? 
 Is higher area-level percent of individuals that moved from a different country associated 
with higher odds of late stage CVC among women in the US, controlling for other 
variables? 
Results 
Descriptive Statistics 
During 2010-2014, 59,360 women were diagnosed with CVC. Approximately 61% of the CVC 
sample is White, 16% is Black, 17% is Hispanic, 1% is American Indian, 4% is Asian and 1% is 
of other race or ethnicity. The sample was also slightly older with an average age of 51 years for 
all CVC cases. The CVC sample also shows that 54.15% of all CVC cases diagnosed during this 
period were late stage diagnoses. However, Figure 1 shows that the proportion of late stage CVC 
diagnoses vary tremendously across counties. For example, at the county level, in 379 counties 
the proportion of CVC cases diagnosed at a late stage was 1 standard deviation above the county 
level average of 56% while the proportion of CVC cases diagnosed at a late stage CVC was 1 
standard deviation below the county level average in 187 counties. Given the substantial 
variability in the proportion of CVC cases diagnosed at late stage across counties, we believe 
both person and county level factors contributed to late stage CVC incidence and disparities. 
Table 2 provides the sample statistics for each of the person and county level study predictors.  
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On average, the county-level percent uninsured and HMO penetration was slightly high at 
18.75% and 15.17%, respectively. On the other hand the average county-level percent poverty 
and percent of individuals that moved from a different country was lower than 1%. We also 
found that there were more FQHC per 100,000 people compared to PPH clinics per 100,000 
people. There were approximately 2.07 FQHC per 100,000 people and less than 1 PPH clinics 
per 100,000 people in the US. In regards to PCP shortage, there was an average county-level 
need of 2.3 FTE PCP in each HPSA. Finally, we found that there was an average of 310 people 
per square mile across counties, indicating that counties were more rural than urban.  
Multilevel Model Results 
In Table 3, we provide the empirical results from multilevel modeling of factors at the person 
and county levels with county-level factors as higher levels of influence. This table   reports 
effect estimates when no interaction term is included in the model, i.e. the base model. 
Examining base model results, we found that Black and Hispanic women with CVC and women 
with CVC who are over the age 50 were associated with higher odds of late-stage CVC 
compared to Whites and women under age 50. Specifically, model estimation shows that the 
odds of late stage CVC among Black women with CVC is 1.34 times the odds of late stage CVC 
among White women with CVC, controlling for all study predictors. Similarly, the odds of late 
stage CVC among Hispanic women with CVC is 1.10 times the odds of late stage CVC among 
White women with CVC, controlling for all study predictors. These findings are consistent with 
the current literature, demonstrating that when controlling for other study variables there are 
racial disparities in late stage CVC diagnoses and that being Black or Hispanic is a risk factor for 
late stage CVC. On the other hand, we found that the odds of late stage CVC among women with 
CVC who identify as “Other” race or ethnicity is 0.46 times the odds of late stage CVC among 
White women with CVC, controlling for all study predictors. Finally, looking at person level 
factors we found that the odds of late stage CVC among women with CVC who are over the age 
50 is 2.70 times the odds of late stage CVC among women with CVC who are under 50, 
controlling for all study predictors. 
At the county level, we found that the percent of the population that moved from a different 
country in the year prior and the number of Planned Parenthood (PPH) clinics per 100,000 
people were negatively associated with stage at CVC diagnosis. Specifically, for every one clinic 
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increase in PPH clinics per 100,000 people, the odds of late stage CVC among women with CVC 
is expected to decrease by 6%, controlling for all study predictors. This suggests that counties 
with more PPH clinics per 100,000 people protects against late stage CVC by providing greater 
opportunities for healthcare services to women with CVC. In regards to the influence of 
immigration, we found that for every 1 percent increase in the county level percent of the 
population that moved from a different country, the odds of late stage CVC among women with 
CVC is expected to decrease by 12%, controlling for all study predictors. On the other hand, the 
percent of uninsured individuals and the percent of individuals in poverty were positively 
associated with late stage CVC diagnoses.  Study results indicate that for every 1 percent 
increase in county level uninsured rates, the odds of late stage CVC among women with CVC is 
expected to increase by 1.01 folds, controlling for all study predictors. Similarly, for 1 percent 
increase in the county level percent of individuals in poverty, the odds of late stage CVC among 
women with CVC is expected to increase by 2.37 folds, controlling for all study predictors. 
These results suggest that counties with higher uninsured and poverty rates are risk factors for 
being diagnosed with CVC at a late stage.   
Table 4 reports the effect estimates of the two interaction models. The estimates for the model 
that includes the cross-level interaction between race or ethnicity and the number of Planned 
Parenthood clinics per 100,000 people are under the column labeled “Interaction 1- PPH 
clinics*Race or Ethnicity”. The estimates for the model that includes the cross-level interaction 
between race or ethnicity and PCP shortage are under the column labeled “Interaction 2- PCP 
Shortage*Race or Ethnicity”.  In the “Interaction 1- PPH clinics*Race or Ethnicity” model, we 
found that age less than 50 and  the county-level percent of the US population that moved from a 
different country in the year prior were still significantly associated with lower odds of late stage 
CVC. Similarly, the county level percent of uninsured and percent in poverty were still 
significantly associated with greater odds of late stage CVC diagnosis.  
Understanding the effect estimates of variables included in an interaction requires computing the 
marginal effects, which involves two terms – the main effect and the interaction effect. The 
estimates in the “Interaction 1” model further suggest that the marginal effect  of PPH clinics per 
100,000 people is associated with a lower probability of late stage CVC among women with 
CVC who are White, Black, and Other race or ethnicity. Conversely, the marginal effect of PPH 
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clinics per 100,000 people is associated with a higher probability of late stage CVC among 
women with CVC who are Asian and American Indian race and ethnicity. However, none of 
these interaction effects were statistically significant. The partial derivatives for these 
insignificant relationships are below: 
dY/dPPH = - 0.03035+(0) (when race or ethnicity= White) = -0.03035  
dY/dPPH = - 0.03035+( -0.1686) (when race or ethnicity = Black) = -0.1989  
dY/dPPH = - 0.03035+(0.0923 ) (when race or ethnicity = Asian) =  0.0619  
dY/dPPH = - 0.03035+(0.3042) (when race or ethnicity =  American Indian) = 0.2738  
dY/dPPH = - 0.03035+(-0.03895) (when race or ethnicity =  Other) = -0.0693  
The interaction between Hispanic ethnicity and PPH clinics per 100,000 people was the only 
statistically significant interaction effect. This estimate suggests that a greater number of PPH 
clinics per 100,000 people is associated with a lower probability of late stage among Hispanic 
women with CVC. 
dY/dPPH = - 0.03035+(-0.1534) (when or ethnicity= Hispanic) = -0.1837  
Estimates further suggest that for every one clinic increase in the number of PPH clinics per 
100,000 people, the probability of late stage CVC among Hispanic women with CVC is expected 
to decrease by 0.1837. This suggests that more PPH clinics per 100,000 people is a protective 
factor for Hispanic women with CVC compared to that for White women.  
The marginal effects of the each of the significant race or ethnicity groups are:  
dY/Black = 0.3248 + (-0.1686)( 0.2004, mean of PPH clinics per 100,000 people) = 0 .2911 
dY/Hispanic = 0.1358 + (-0.1534)( 0.2004, mean of PPH clinics per 100,000 people) = 0.1051 
dY/Other = -0.684+ (-0.3895)( 0.2004, mean of PPH clinics per100,000 people ) =  -0.7620  
These estimates suggest that the marginal effects of Black and Hispanic race or ethnicity are 
associated with higher probabilities of late stage CVC among counties with mean/average 
numbers of PPH clinics per 100,000 people. The marginal effect of Hispanic race or ethnicity 
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suggests that the probability of late stage CVC among Hispanic women with CVC is 0.1051 in 
counties with mean/average numbers of PPH clinics per 100,000 people. The marginal effect of 
Black race or ethnicity suggests that the probability of late stage CVC among Black women with 
CVC is 0 .2911 in counties with mean/average numbers of PPH clinics per 100,000 people. On 
the other hand, the marginal effect of Other race or ethnicity is associated with a lower 
probability of late stage CVC among counties with mean/average numbers of PPH clinics per 
100,000 people.  The probability of late stage CVC among women of Other race or ethnicity 
with CVC is -0.7620 in counties with mean/average numbers of PPH clinics per 100,000 people. 
In regards to the “Interaction 2- PCP Shortage*Race or Ethnicity” model, the association 
between the odds of late stage CVC and each of the covariates were the same in this model as 
they were in the “Interaction 1- PPH*Race or Ethnicity” model. Specifically, race or ethnicity, 
age less than 50, area-level percent of individuals that moved from a different country and area-
level poverty, uninsured rates were statistically significantly associated with the odds of late 
stage CVC among women with CVC in the US.  However, we found no statistically significant 
interaction effects between race or ethnicity and PCP shortage. 
Discussion 
Current literature suggests that access to health care is impacted by factors at various levels, yet 
most of the studies investigating late stage CVC and disparities have examined factors occurring 
strictly at the individual level.
 42-44
 However, we found that there is extreme variability in the 
proportion of late stage CVC cases across counties (Figure 1), which suggests  there may be 
county level factors influencing stage at diagnosis among women with CVC. Thus, we add to the 
literature by assessing access to care barriers occurring at the county level while accounting for 
some consistently identified individual level factors associated with late stage CVC as well. 
Given the increased need for primary care physicians 
28
 and uninsured populations
27
 we further 
narrowed our focus to the influence of availability and affordability related indicators of access 
to care. Ultimately, our study goals were to identify the access to care barriers associated with 
late stage diagnosis and determine how the relationship between these barriers and stage at CVC 
diagnosis differed by race or ethnicity. We found that area-level percent in poverty, percent 
uninsured and percent that moved from a different country and Planned Parenthood clinics per 
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100,000 people were each associated with late stage CVC diagnosis. However, primary care 
physician shortage areas were not a significant predictor of late stage CVC.  
While poverty and uninsured status have previously been identified in the literature as individual 
level risk factors for late stage CVC diagnosis, to our knowledge this is the first time they have 
been identified as significant county level risk factor for late stage CVC. This suggests that not 
only  are individual socioeconomic status (SES) and insurance status risk factors for late stage 
CVC diagnosis but that  the average SES and percent insured among the county in which a 
woman lives  is also a risk factor for late stage CVC diagnosis. This highlights the need for more 
county-wide interventions and policy reforms to increase CVC screening rates by developing 
more affordable or free screening solutions and helping individuals to overcome barriers to 
health care coverage. This also highlights the need to develop and implement multilevel 
interventions to address barriers to screening access that occur not only at the individual level but 
the community, health care service, and policy levels as well. Many researchers have shown that 
when an ecological model-based approach is used to develop intervention strategies that target 
multiple levels, we are most likely to achieve substantial and sustained change.
60-63 
 
Findings regarding the influence of county level percent poverty and percent uninsured further 
highlight that lack of health insurance coverage and poverty are important access barriers 
associated with stage at CVC diagnosis.  This discovery suggests that there is a need to identify 
and determine the magnitude of the effects of those factors likely working to circumvent the 
protective effects of the provisions under the ACA. For example, commercial health insurance 
inside and outside of the health exchanges are exempt from the ‘no cost sharing’ feature of the 
preventive services provision under the ACA when preventive services are not delivered by a 
network provider.
64 
Similarly, private health plans that existed prior to March 23, 2010 were 
considered to be ‘grandfathered plans’ and were exempt from required coverage for preventive 
services under the ACA, including CVC screening.
65 
It is likely that as a result of both of these 
loopholes, large proportions of varies populations remained in a position where they were unable 
to afford healthcare. Thus, these loopholes may explain why area-level percent poverty (i.e. 
affordability) is still a barrier associated with stage a CVC diagnosis during 2010-2014. 
Ultimately, these loopholes and other ACA opposing factors such as non-Medicaid expansion 
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states should be investigated to determine the impact they have on access to CVC screening and 
stage at diagnosis. These findings could likely highlight the need for further health policy reform.    
Unlike area-level percent poverty and percent uninsured indicators, the relationship between 
Planned Parenthood clinics per 100,000 people and late stage CVC has never been explored. 
However, the number and distribution of these clinics reflects availability of primary care 
providers and affordability of women health services such as CVC screening as these clinics 
provide services at low or no cost. Thus, we were not surprised to find that counties with more 
PPH clinics per 100,000 people were associated with decreased odds of late stage CVC among 
women with CVC. Although there is continued political controversy related to PPH clinics 
because of their provision of abortion care
66
 their importance in providing CVC screening 
services and reducing the likelihood of late stage CVC cancers is clearly demonstrated in this 
study. These results are of extreme relevance, as Planned Parenthood announced that they would 
voluntarily withdraw from Title X federal family funding programs, which provides PPH with 
nearly $60 million annually, rather than comply with new laws that forbids referrals to doctors 
who can perform abortions.
66
 Based on our results, it is our hypothesis that a significant lost in 
funding would restrict access to PPH clinics CVC screening services and thus impose a greater 
burden of late stage CVC, specifically among Hispanic women.  
We were also not surprised to find that among the racial disparities we identified in this study, a 
higher number of PPH clinics per 100,000 people were significantly associated with lower odds 
of late stage CVC among Hispanic women. Planned Parenthood clinics provide services to more 
than 560,000 Latina patients each year.
67
 We believe PPH clinics large Latina service population 
and the protective effect identified in this study is likely the result of PPH clinics highly 
publicized commitment to provide affordable primary and preventive services to all regardless of 
factors including immigration status.
68
 The second likely explanation for this protective effect is 
that PPH clinic led groups have implemented several effective interventions aimed at increasing 
CVC screening among Hispanic women across the US. For example, the local chapter of 
Planned Parenthood of Wisconsin led a successful community-based intervention called 
Cuidándome that aimed to increase cervical and breast cancer screening among low-acculturated 
Latinas in Dane County, Wisconsin.
69
 It is likely that similar PPH clinic led interventions exist 
across the US and that they have been successful in preventing late stage CVC among Hispanic 
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women by increasing access to screening services. In fact, a map of PPH clinic Latinx Advocacy 
Programs shows that these programs are active in 19 states including: Arizona, California, 
Colorado, Connecticut, Florida, Illinois, Massachusetts, Minnesota, New Mexico, New York, 
Nevada, Pennsylvania, Rhode Island, Tennessee, Texas, Utah, Virginia, Washington, and 
Wisconsin.
67
  
The final possible explanation for the observed protective effect is that there are effective 
measures in place for increasing the intent to screen for CVC among Hispanic women and PPH 
clinics are the most proximal clinics to most Hispanic populations. Figure 2 shows that Hispanic 
women are heavily concentrated in counties within Texas, New Mexico, Arizona, California, 
Colorado and Idaho. Similarly, Figure 3 shows that the number of PPH clinics per 100,000 
people is highest within counties in Texas, Colorado, Arizona, California, Iowa and Washington. 
Thus, we believe it could be the overlap in the distribution of Hispanic women and PPH clinics 
geographically that allow Hispanic women to benefit most from PPH clinic services. Based on 
Figure 4, we also believe that those 7 counties colored black in both Texas and Colorado are the 
main forces driving the observed protective effect. These places represent those counties that 
have both the largest proportion of Hispanic women with CVC and the highest number of 
Planned Parenthood clinics per 100,000 people compared to other counties, representing places 
where Hispanic women are most benefitting the PPH clinic screening services. Overall, mapping 
results suggest that if there was a more random spread of PPH clinics across geography racial 
disparities in late stage CVC among Hispanics and other minority groups serviced by PPH 
clinics could also be potentially reduced.  
While we were not surprised to find that Hispanic women were disproportionately burdened by 
late stage CVC or that this disparity could be partially explained by an access barrier, we were 
surprised to find that higher immigration rates were associated with lower odds of late stage 
CVC. Given that the existing literature has consistently found that Hispanic women are 
associated with greater odds of late stage CVC
3-4, 49 
and that Hispanics are the largest immigrant 
population in the US
70
, we expected that higher county-level percentages of the US population 
that moved from a different country during the prior year would be associated with higher odds 
of late stage CVC. However, previous research among 32 US immigrant groups found that 
nearly all immigrants were more educated than those who remained in their home countries
71 
and 
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other findings suggests that higher education levels are associated with higher cervical cancer 
screening rates.
72
 Thus, it is plausible that educational selectivity in US immigration likely 
explains the observed relationship between higher percentages of 
 
the US population that moved 
from a different country during the prior year and lower odds of late stage CVC diagnosis.  
On the other hand, this finding could indicate that the majority of the immigrant population 
represented with this variable during 2007-2011 may have come from countries with effective 
Pap screening interventions. If these individuals came from countries with heavily implemented 
screening programs, which could have focused on education, affordability or accessibility, it 
would explain why higher county-level percentages of the US population that moved from a 
different country during the prior year would be associated with higher odds of late stage CVC. 
However, additional research is needed to better understand this relationship. Overall, this study 
demonstrates that there are still significant access barriers associated with the odds of late stage 
CVC among women in the US and that these barriers can occur beyond the individual level. This 
suggests that by the time period 2010-2014 there is still a need to develop strategies for 
improving availability and affordability of health care services including CVC screening. This 
further highlights the importance of assessing multiple levels of influence to develop a 
comprehensive understanding of the problem and the pathway to these problems. Additional 
research is needed to determine whether access to care barriers at the state level may also play a 
role in stage at CVC diagnosis. Research is also needed to further explore multilevel factors 
associated with late stage CVC among Black women and women over the age of 50 as they were 
found to be disproportionately affected. The odds of late stage CVC among Black women was 
not significantly associated with the two access to care indicators tested in this study, PCP 
shortage and PPH clinics per 100,000 people. However, study results have indicated that access 
to care is still a significant predictor of stage at CVC diagnosis. Thus, it is essential to continue to 
explore the relationship between racial disparities in stage at CVC diagnosis and access to care 
barriers that may occur at other levels of influence. Further identifying the multilevel factors 
associated with late stage diagnosis and disparities is essential as CVC stage at diagnosis plays a 
significant role in cervical cancer treatment, prognosis and survival.
73  
Failing to address the 
identified access to care barriers and investigate relationships that remain unclear will result in 
continued high CVC mortality rates and persistent racial disparities in these outcomes.  
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Figure 1 
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Table 2: Descriptive Statistics 
Variable Name Mean or percent Standard 
deviation 
Minimum and 
maximum values 
Person compositional  
Variable (n=59,360) 
Late Stage CVC Diagnosis 
0 
1 
 
30184(50.85%) 
29176(54.15%) 
 
NA, binary 
variable 
 
NA, binary 
variable 
 
Race or Ethnicity 
0 non-Hispanic White (ref) 
1 non-Hispanic Black 
2 Asian 
3 American Indian 
4 Hispanic 
5 Other 
 
 
36116(60.84%) 
9229(15.55%) 
2615 (4.41%) 
538 (0.91%) 
10193(17.17) 
669(1.13%) 
 
 
NA, categorical 
variable 
 
 
NA,  
categorical  
variable 
 
Age <-50 
0 
1 
 
 
30184(50.85%) 
29176(49.15%) 
 
 
NA, binary 
variable 
 
 
NA, binary 
variable 
 
Age 
 
51.3679245 
 
15.2647831 
 
- 
County contextual  
Variable (n=2,357) 
Percent Moved From 
Different Country 
 
0.320 0.420 0, 7.34 
Percent HMO Penetration 
 
15.1734 9.4779 1.7114, 42.087 
Percent Uninsured 
 
18.7532 5.4156 3.60, 41.40 
Percent Poverty 
 
16.40 6.48 3.44, 53.49 
FQHCs per 100,000 people 
 
2.0748 4.8789 0,100.35 
PPH clinics per 100,000 
people 
 
0.2004 0.7267 0, 9.344 
PCP-shortage 
 
2.3211 3.5861 -11.57*, 35.15 
Urbanicity=pop10/land 310.4118 1971.6079 0, 69178.9916 
 
*A maximum county-level PCP shortage of 35.15 indicates that there is a need for roughly 35  
additional full-time equivalent (FTE) PCPs in a Health Professional Shortage Area (HPSA) in  
order to achieve the population to PCP target ratio (3,500 to 1).Similarly a  minimum county- 
level PCP shortage of -11.57 indicates that there are roughly 12 more FTE PCPs in a HSPA  
than what is needed to achieve the population to PCP target ratio (3,500 to 1). 
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Table 3 : Multilevel Model Results without Interactions - Base Model 
Covariate Coefficient  Error p-value 
Person compositional  
variable 
Intercept 
 
0.4331 0.05657 <.0001 
Race or Ethnicity 
0 non-Hispanic White (ref) 
1 non-Hispanic  Black 
2 Asian 
3 American Indian 
4 Hispanic 
5 Other 
 
0 
0.2906 
0.06239 
0.1532 
0.09638 
-0.7800 
 
- 
0.02866 
0.04745 
0.1001 
0.02826 
0.1159 
 
- 
<.0001 
0.1886 
0.1257 
0.0006 
<.0001 
Age < 50 
0 (ref) 
1 
 
0 
-0.9933 
 
- 
0.01909 
 
- 
<.0001 
County contextual  
variable 
Percent Poverty 
 
0.8642 0.2672 0.0012 
Percent HMO Penetration 0.000917 0.001185 0.4390 
Percent Uninsured 
 
0.006774 0.002611 0.0095 
Percent Moved From Different 
Country 
 
-0.118428 0.031861 0.0002 
Urbanicity=pop10/land -2.98E-7 2.242E-6 0.8942 
FQHCs per 100,000 people -0.00218 0.005525 0.6927 
PPH clinics per 100,000 people -0.05681 0.02820 0.0439 
PCP shortage -0.00045 0.002007 0.8225 
 
Variance Components 
(county level) 
 
0.01736 
 
0.005097 
 
- 
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Table 4 : Multilevel Model Results with Interactions 
 Interaction 1 –PPH*Race or Ethnicity  Interaction 2- PCP Shortage*Race or 
Ethnicity 
Covariate Coefficient  Error p-value Coefficient  Error p-value 
Person compositional  
variable  
Intercept 0.4247 0.05652 <.0001 0.4382 0.05655 <.0001 
 
Race or Ethnicity 
0 non-Hispanic White 
(ref) 
1 non-Hispanic  Black 
2 Asian 
3 American Indian 
4 Hispanic 
5 Other 
 
 
 
0 
0.3248 
0.04221 
0.06837 
0.1358 
-0.684 
 
 
 
- 
0.03523 
0.06702 
0.1245 
0.03513 
0.1559 
 
 
 
- 
<.0001 
0.5288 
0.583 
0.0001 
<.0001 
 
 
 
0 
0.2668 
0.06328 
0.1768 
0.1055 
-0.8264 
 
 
 
- 
0.03842 
0.07169 
0.1345 
0.03977 
0.1553 
 
 
 
- 
<.0001 
0.3774 
0.1888 
0.008 
<.0001 
 
Age < 50 
0 (ref) 
1 
 
 
0 
-0.993 
 
 
- 
0.01909 
 
 
- 
<.0001 
 
 
0 
-0.9937 
 
 
- 
0.01909 
 
 
- 
<.0001 
County contextual  
Variable 
Percent Poverty 
 
0.9258 0.2621 0.0004 0.909 0.2623 0.0005 
Percent HMO 
Penetration 
 
0.000894 0.001181 0.4491 0.00085 0.001186 0.4733 
Percent Uninsured 
 
0.006852 0.002604 0.0085 0.006697 0.002618 0.0105 
Percent Moved From 
Different Country 
 
-0.121426 0.031614 0.0001 -0.120177 0.031785 0.0002 
Urbanicity=pop10/land -4.09E-07 2.23E-06 0.8546 -4.31E-07 2.26E-06 0.8489 
FQHCs per 100,000 
people 
 
-0.00132 0.005191 0.7992 -0.00094 0.005195 0.8558 
PPH clinics per 100,000 
people 
 
-0.03035 0.03139 0.3336 -0.05897 0.02812 0.0360 
PCP shortage 
 
-0.00087 0.001978 0.6614 -0.00101 0.002357 0.6674 
Race* PPH clinics per 
100,00 capita 
0 non-Hispanic White 
(ref) 
1 non-Hispanic Black 
2 Asian 
3 American Indian 
4 Hispanic 
5 Other 
 
 
 
0 
-0.1686 
0.09233 
0.3042 
-0.1534 
-0.3895 
 
 
 
- 
0.102 
0.1907 
0.2684 
0.07961 
0.4352 
 
 
 
- 
0.0982 
0.6283 
0.2571 
0.0531 
0.3708 
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Race* PCP Shortage 
0 non-Hispanic White 
(ref) 
1 non-Hispanic Black 
2 Asian 
3 American Indian 
4 Hispanic 
5 Other 
  
 
 
 
 
 
0 
0.003085 
0.000155 
-0.00454 
-0.00083 
0.006918 
 
 
- 
0.003594 
0.005745 
0.01864 
0.003352 
0.01521 
 
 
- 
0.3907 
0.9784 
0.8074 
0.8051 
0.6492 
Variance Components 
(county level) 
 
0.01692 
 
0.005097 
 
- 
 
0.01755 
 
0.005098 
 
- 
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Figure 2 
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Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Percent of Hispanic Women with CVC Across Counties in the U.S. 
(Standard Deviation Map) 
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Figure 4 
 
 
 
 
 
 
  
 
 
 
 
Bivariate Map of Planned Parenthood Clinics per 100,000 people and Percent of Hispanic 
Women with CVC in the U.S. 
 
Legend of Bivariate 
Categories 
(Number of Counties in Each 
Category Included) 
Percent of Hispanic Women 
Planned Parenthood Clinics 
 per 100,000 people 
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Chapter Four: Multilevel Access Barriers Influencing Geographic Disparities in Late Stage 
Cervical Cancer among Counties in the U.S. 
Introduction  
Due to early detection of  precancerous cervical cell changes and early stage cancers via Pap 
testing, cervical cancer (CVC) is one of the most preventable cancers in the US.
1
 However, more 
than 50% of women with CVC in the US are diagnosed at a late stage (regional or distant).
2
 
Specifically, the Surveillance, Epidemiology, and End Results (SEER) program indicates that 
36% of the CVC cases were diagnosed at regional stage and 15% at distant stage.
2
 Regional and 
distant stage CVC diagnoses are associated with poor prognosis, increased morbidity and lower 
5-year survival rates.
3
 In fact, the 5-year survival rate for localized cervical cancer is 91.7%, 
compared to a 5 year survival rate of 56% for regional cervical cancer and 17% for distant 
cervical cancer.
2 
Existing literature suggests that the burden of late stage CVC is unequally distributed among 
people and places in the US.
4-5
 Late stage CVC has been found to disproportionately burden 
African American
4-5
 and Hispanic
4
 women and women who are over the age of 50.
4
 Foreign born 
women
6
, women without health insurance
7
 and women with lower incomes
8
 have also been 
found to be disproportionately burdened by late stage CVC. Previous research further suggests 
that disparities in late stage CVC incidence exist between different geographic populations.
4,9-11
 
According to a 2013 study investigating late stage CVC in Central Appalachia, there was 
significant variability in the incidence of late stage CVC across counties in the state of Ohio.
9
 A 
later 2014 study found that there was significant variability in stage at CVC diagnosis among 
4,388 census tracts in the state of Texas (TX).
10
 Major findings from this study indicate that 
clusters with statistically significantly increased risk for late stage CVC were located in the 
Western tip of TX, Southern TX, the Bryan/College State area and central Houston.
10
 A third 
geographic disparities study also found considerable differences in late stage CVC incidence 
among census tracts within the state of New Jersey (NJ).
11
 Specifically, this study identified 
three significant late stage CVC high incidence areas in: northeastern NJ, central NJ and 
Southwestern NJ.
11
  
93 
 
Identifying the factors associated with geographic variability in stage at CVC diagnosis is an 
essential approach to strategically targeting places in need of CVC prevention and control. 
However, research that aims to answer questions related to where there is a need for intervention, 
requires an ecological approach that uses groups rather than individuals as the unit of study. 
Previous ecological studies have found that a number of compositional and contextual factors are 
associated with CVC screening and stage at diagnosis.
12-17
 Among these factors are area level 
socioeconomic status (SES)
10,
 
12
and community-level age, race and immigrant composition.
10,13
 
Studies have also shown that contextual factors impacting access to care are associated with 
CVC screening and stage at diagnosis.
10,14-16
 Specifically, the literature suggests that health 
services resources in the community, travel time to the nearest screening facilities and 
availability of services in the community represent contextual access to care factors associated 
with CVC screening and stage at diagnosis. 
10, 14-16
 
Although several compositional and contextual factors influencing CVC screening and stage at 
CVC diagnosis have been documented, there are still a number of gaps in the existing literature. 
First, no study has described the county-level variation in stage at CVC diagnosis for nearly the 
total US (n=43 states). In fact, many of the investigations of geographic disparities in screening 
and stage at diagnosis have been limited to a single state or performed at the census tract level.
9-
11
 Second, because previous studies have been limited to a single state, no study has identified 
the contextual factors that may help to explain the variation in late stage CVC that potentially 
exists among all counties in the US. Third, in regards to research aimed at identifying factors 
associated with screening and stage at CVC diagnosis a number of contextual access to care 
factors have been unexplored, including health policies.  
Recent studies suggest that the most significant predictor of late stage CVC is whether or not a 
woman has had a Pap test in the past 3 years (i.e. current screening), which is largely attributed 
to access to care.
5,17-19
 However, access to CVC screening has been consistently found to be 
unequal across various populations in the US.
20 
 The observed variability in access to CVC 
screening across populations thus highlights the importance of focusing on contextual access to 
care in order to explain the geographic variability in late stage CVC. The persistent variability in 
access to care across populations over time also highlights the need to focus of those contextual 
access to care factors that have been less commonly explored, including health policies.
12, 21
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Given the limitations in the existing literature, this study aims to 1) identify county-level 
disparities in late stage CVC across (n=43 states)and 2) explain the observed disparities by  
identifying statistically significant ecological relationships between high proportions of late stage 
CVC diagnoses in counties and several county and state-level variables. Using a hybrid model 
that draws from the Access to Care Framework
22
 Theory of Access
23
 and Socio-ecological 
model
24
, we specifically explore the relationships between late stage CVC and several indicators 
of access to CVC screening. Among the study variables we are most interested in are unexplored 
access to care factors that are determined by state policy including: state policies regarding scope 
of practice for nurse practitioners, state healthcare insurance CVC screening mandates and state-
level proportions of individuals enrolled in self-insured employer-sponsored insurance plans. 
Each of these three state-level variables is described further below. 
Nurse Practitioner Regulations 
Nurse practitioners (NPs) are advanced practice registered nurses (APRN) that provide quality 
care, yet receive training and enter the healthcare system in less time than their physician 
colleagues.
25 
According to the American Academy of Nurse Practitioners, there are 
approximately 140,000 NPs in the US
26 
with over 50% of the NP workforce practicing in 
primary care settings.
27
  
 Because NPs play such an important role in primary care, they have also been found to play a 
substantial role in providing  cervical cancer screening tests.
28 
A recent systematic review found 
that among 5 studies evaluating the role of NPs in Pap testing, 72%-98% of APRNs reported that 
they routinely provided or recommended Pap tests to patients.
29
 This review also found that in 
most studies physicians reported being amenable to APRNs conducting Pap tests.
29
 Overall, the 
incorporation of NPs into the healthcare delivery system has increased overall access to 
healthcare
30 
and has also been associated with reaching previously unscreened and under-
screened women at risk for cervical cancer.
26 
Despite the known benefits of having NPs in the healthcare delivery system, there are several 
barriers that prevent them from being fully deployed. Among those barriers are state-based 
regulations governing NP scope of practice. These regulations can restrict or prevent NPs from 
practicing to their full potential. While some states allow NPs full scope of practice, including 
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the ability to evaluate, diagnose, treat, and prescribe under the exclusive licensure authority of 
the state board of nursing, others impose restrictions, requiring supervision, delegation, or team 
management by a physician in order to provide patient care, and limiting engagement in at least 
one element of practice.
31
 Recent data indicate that 22 states and the District of Columbia allow 
NPs full scope of practice and 29 states impose restrictions on their practice.
31
  
Many argue that complying with restrictive scope of practice laws could take time from both 
NPs and their supervising physicians
32 
and limit the supply of health services.
33 
We hypothesize 
that states with restrictive NP scope of practice laws are associated with poorer access to quality 
care and consequently higher proportions of late stage cervical diagnoses.  
Cervical Cancer Screening Mandates & Self-Insured Plans 
Since the early 1960s, requirements regarding coverage provisions of private health insurance 
policies has largely fallen under the jurisdiction of state governments.
34
 Mandated state insurance 
coverage requirements were established in efforts to promote public health and improve access 
and treatment for people with specific diseases, including cancer.
34
 State cancer mandates now 
include requirements for screening, prevention and treatment. In 2009, there were approximately 
25 cancer-related insurance mandates across states.
34
Among those mandates, only two focused 
specifically on cervical cancer: required cervical cancer screening and Human Papillomavirus 
(HPV) vaccination. In regard to required cervical cancer screening mandates, there is significant 
variation across states. By 2009, thirty-two states and the District of Columbia required insurers 
to cover cervical cancer screening while 19 did not.
34 
While state CVC screening mandates are now perhaps less important, following the 
implementation of new preventive services coverage provisions under the Affordable Care Act 
(ACA) from 2012-2014, there are still reasons to expect that they may be significant predictors 
in the models estimated here.  First, they established a stronger baseline in states that adopted 
them prior to 2010 that was absent in other states.  Thus, these states were poised to perform 
better than states who saw these requirements for the first time in 2010.  Several other factors 
suggest the importance of state mandates in supporting access to healthcare.
35-38
 For example, 
private health plans that existed prior to March 23, 2010 were considered ‘grandfathered plans’ 
and were exempt from required coverage for preventive services under the ACA, including CVC 
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screening.
36 
 Similarly, commercial health insurance inside and outside of the health insurance 
exchanges are exempt from the ‘no cost sharing’ feature of the preventive services provisions 
under the ACA when preventive services are not delivered by a network provider.
37 
These types 
of loopholes reduced the potential for federal ACA mandates to achieve their intended effects on 
access to healthcare by exempting large portions of the insured population. Furthermore, a 
systematic review of studies investigating the ACA’s impact on cancer screening and diagnosis 
found that the impact on changes in screening in the general population was mixed.
38
 Together 
these loopholes and findings suggest that state mandates may still play a significant role in 
access to healthcare post-ACA implementation in 2010. 
In 2013, Miles-Richardson et al. examined the impact of state cervical cancer screening 
mandates on screening rates and racial disparities in screening rates among women in Georgia, 
North Carolina and South Carolina and found no significant effects.
39 
However, a later 2017 
study found that Pap test mandates increased past-2-year screening rates by 1.3 percent. 
Additional results from this study suggest that the effects of the mandate on screening rates were 
significantly larger among Hispanic women.
40
 
We believe findings suggesting a relationship between CVC screening and state cancer-related 
insurance mandates have been inconsistent because there may be significant lags in effects, so 
later studies may find larger effects.  Also, studies have not considered  important contingencies 
related to private sponsorship of self-insured plans,  although these plans account for more than 
50% of persons with employer-sponsored health insurance.
41
 According to provisions under the 
Employee Retirement Income Security Act (ERISA), private employer self-funded plans are 
exempt from most state insurance laws, including mandated benefits.
42
 However, self-funded 
plans established by public employers are not exempt from state insurance laws.
42 
  Thus the 
effects of these state mandates may depend upon how much of the self-insured population is in 
public or private plans. 
We hypothesize that states with CVC screening mandates are associated with lower county-level 
proportions of late stage CVC compared to states without these mandates. However, we 
hypothesize that this relationship will also be impacted by the percentage of the state population 
in private self-insured plans, as these plans can avoid the protective effect of mandates. 
Therefore, we hypothesize that higher proportions of the state population in private self-insured 
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plans will be associated with higher proportions of late stage CVC in places with and without 
state CVC screening mandates. Yet, because this relationship has never been explored, we are 
uncertain whether the effect of this barrier will be greatest in places with or without mandates. 
However, understanding this relationship is essential as the number of private self-insured plans 
has increased over time. We are not able to control separately for employees in private versus 
public self-insured plans, however our data include all individuals in private self-insured plans.
43 
Conceptual Model 
As previously stated, the most significant predictor of late stage CVC is whether or not a woman 
has had a Pap test in the past 3 years (i.e. current screening), which is largely attributed to access 
to care.
5,17-19
 However, access to CVC screening has been consistently found to be unequal 
across various populations in the US.
20 
 Given the significance of access to CVC screening in the 
etiological pathway to late stage diagnosis, it is critical to identify factors contributing to unequal 
access to CVC screening (i.e. access to screening barriers) to better understand stage at CVC 
diagnosis outcomes.  
Based on the existing literature, we know that unequal access to cervical cancer screening and 
late stage CVC diagnosis are both influenced by complex and interacting social, environmental 
and behavioral processes that occur at varying geographical and socioecological levels.
44   
However, current research investigating disparities in stage at cervical cancer diagnosis and 
access to CVC screening has not focused on the simultaneous effects of factors occurring at 
multiple geographical and socioecological levels. In fact, a review of the literature indicates that 
most of the studies on this topic limit their investigations to one level of influence at a time, with 
individuals being the most common socioecological level and census tract being the most 
common geographical level. 
44-48
 Thus, we do not have knowledge of the effects of several 
factors that lie at the health policy level and we do not know whether the effects of previously 
studied variables hold true when accounting for significant factors that lie at other geographic 
scales/levels. This is important because failing to account for multilevel factors and 
compositional characteristics of the study population - which helps control for migratory 
population selection effects - has been found to significantly bias regression estimates.
49  
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To address the concerns raised in the recent literature and achieve reliable estimates, we 
developed a multilevel conceptual model for understanding access to CVC screening and late 
stage CVC outcomes by drawing from the current literature, the socio-ecological
24
 model and 
both Aday and Andersen’s 1974 Access Framework
22
 and Penchansky and Thomas’s 1981 
Theory of Access.
23,50 
This hybrid model describes the influence and spatial interactions among 
two geographical and socioecological levels. Level 2 represents the policy level of the socio-
ecological model and includes health policy factors that vary across states. Level 1 represents 
both the community and institutional levels of the socio-ecological model and includes 
compositional and contextual factors that vary across counties. The compositional factors 
included in the model were mostly selected to represent what Aday and Andersen define as 
predisposing and enabling characteristics of the population at risk. The contextual factors 
included were selected to reflect what Penchansky and Thomas define as availability, 
affordability and accessibility factors. Each of the variables in the model have been found or are 
hypothesized to influence stage at CVC diagnosis. However, more aspects are listed than can be 
modeled using currently available data or computing power. We describe the specific variables 
used and a rationale for using them in the methods section below. 
Ultimately, it is our hypothesis that there are significant county-level disparities in late stage 
CVC diagnosis. It is also our hypothesis that these geographical disparities can be explained by 
several unexplored access to care barriers that vary based on place. Identifying the factors 
associated with geographic variability in stage at CVC diagnosis is an essential approach to 
strategically targeting places in need of CVC prevention and control. It is also essential for 
informing health policy aimed at improving access to care and developing community-level 
interventions. To our knowledge, this will be the first study to use multilevel modeling to 
understand multilevel CVC screening access barriers and their effects on late stage CVC 
diagnosis.  
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Figure 1: Model of Cross-Level Interactions Influencing CVC Stage at Diagnosis and Disparities  
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Methods 
Study Population 
This study examined all primary cervical cancer cases diagnosed during the years of 2010-2014, 
from the United States Cancer Statistics (USCS) database, available at the National Center for 
Health Statistics Research Data Center.
51
 This database collects information on cancer incidence 
and survival from registries that have high quality data representing 98% of the US population.
51
 
Included in the database is information on demographics (age, gender, race, and ethnicity), tumor 
characteristics, and geographic location (county of residence) at time of diagnosis.
51
 Only those 
researchers with approved research plans are granted access to the database and all analyses must 
be conducted inside secure Federal Research Data Centers (RDCs). 
All states participate in USCS registry data system database. However, five states (Kansas, 
Illinois, Michigan, Minnesota and Missouri) did not allow us to use county of residence 
information.
51
 We excluded these five states and two additional states, Alaska and Hawaii, 
because of missing contextual data. The study sample was further restricted to include all 
persons having cervical cancer and excluded records when this was not their primary cancer or 
when records showed unknown cancer stage or unstaged cancer. These restrictions resulted in 
59,360 individuals diagnosed with cervical cancer living in 43 states during 2010-2014. 
We examined cases within the database during 2010-2014 because this time period represents 
the beginning of a significant time period in the US, with the implementation of the Affordable 
Care Act (ACA).  Beginning in 2010, provisions under the ACA resulted in thousands  of 
individuals with pre-existing conditions obtaining health insurance through a national high-risk 
pool program.
52
 Provisions under the ACA also resulted in millions of women gaining full 
coverage for CVC screening via provisions mandating coverage of preventive services without 
cost-sharing beginning in 2012 and millions of people obtaining health insurance via Medicaid 
expansion and individual health insurance marketplace subsidies beginning in 2014 .
53
 
Therefore, we expect that access to care barriers and their relationships with health outcomes 
during the time period 2010-2014 will considerably be different than those observed during any 
time period prior to 2010.  
Outcome Variable 
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Cervical cancer cases were categorized into late stage (regional and distant) or early stage 
(localized, including in situ) diagnosis. We then created a county-level proportion of late stage 
diagnoses variable. This variable aggregated the total number of late stage cases within each 
county by Federal Information Processing Standard (FIPS) code and divided this by the total 
number of CVC cases within each county. The overall county-level proportion of CVC case 
diagnoses at late stage during the study period is .556 or 56%.  
County-Level Explanatory Variables 
In regard to compositional study predictors, we extracted two person-level covariates from the 
USCS database and aggregated them to the county-level: race or ethnicity and age. Combining 
USCS’s race and Hispanic variables we created six race or ethnicity variables describing the 
percent of women in each county who are: non-Hispanic White, non-Hispanic Black, Hispanic, 
Asian Pacific, American Indian or other. According to the current literature, Black and Hispanic 
women have the highest incidence of CVC, are significantly less likely to be screened for CVC, 
and are more likely to be diagnosed at a late stage.
4-5
 Therefore, we account for this demographic 
composition in our model because we expect that places with higher proportions of women with 
CVC who are Black or Hispanic will be associated with higher proportions of late stage CVC. 
The age variable represents the proportions of women with CVC who are age less than 50. 
According to the literature, older women and women over the age of 50 are significantly more 
likely to be diagnosed at a late stage.
4, 7
 Therefore, we control for this demographic composition 
in our model because we expect that places with higher proportions of women with CVC who 
are age less than 50 will be associated with lower proportions of late stage CVC.  
Other county-level contextual variables were extracted from a number of external data sources. 
The percent of the general population ages 18-64 that speak English poorly (2007-2011) variable 
was obtained from the American Community Survey (ACS).
54
 The literature suggests that 
Hispanic and foreign-born women have greater odds of late stage CVC.
4,6 
The literature also 
suggests that recent immigration status and poor language proficiency are significant barriers to 
CVC screening among Hispanic populations.
55-56
 Therefore,  we control for this variable in our 
model because we also expect that places with a higher percent of the population ages 18-64 that 
speaks English poorly will be associated with higher proportions of late stage CVC.  
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Data describing county level population density (i.e. urbanicity) and the number of counties that 
were persistently poor for three decades in 2010 were extracted from the Economic Resource 
Services (ERS) agency.
57
 According to the literature, late stage CVC diagnosis and access to 
CVC screening are significantly associated with both geography and socioeconomic status 
(SES).
4,8
 Studies suggest that women with lower income and in specific regions of the US are 
more likely to be diagnosed at a late stage.
4,8
 Further, a study by Aker et al. reported that women 
in rural areas and those in economically deprived non-rural communities are less likely to screen 
for CVC and report lower screening rates compared to women in urban and suburban 
areas.
55
Another 2014 survey study investigating rural populations and CVC screening also found 
that 71% of rural Appalachian respondents reported “not being able to use public transportation 
to get to medical appointment” as a barrier to screening.
58
  Therefore, we include these county 
area contextual variables in our model to determine whether places that are less urban and places 
that are persistently poor are associated with higher proportions of later stage CVC.  
The Health Professional Shortage Area (HPSA) score variable, which represents the score for 
determining priorities for assignment of clinicians within Primary Care Physician (PCP) shortage 
areas was obtained from the Health Resources and Service Administration (HRSA) database.
59
 
Scores range from 1-26, with higher scores reflecting greater priority and greater need. The 
number of Federally Qualified Health Centers (FQHC), Planned Parenthood (PPH) clinics and 
Title X-funded centers was obtained from Guttmacher Institute’s Contraceptive Needs and 
Services 2013 data report. We recoded each of the three health center count variables into rates 
per 100,000 people by multiplying each of the counts by 100,000 and dividing the product by the 
total US population for each county in 2010. The relationships between either high priority PCP 
shortage areas, or availability of federally funded health centers per 100,000 people with 
proportions of late stage CVC have never been explored. It is our hypothesis that these variables 
represent essential access to care barriers that will significantly impact the pathways to screening 
utilization and from screening to stage at CVC diagnosis. Specifically, we expect that the HPSA 
score represents lack of availability of CVC screening services, a known dimension of access to 
care. Similarly, the per-capita number of federally funded health centers represents both 
availability of services and affordability of CVC services, as these centers were developed with 
the specific goal of providing high quality and comprehensive primary care to medically 
underserved populations, regardless of their ability to pay.
60-61
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State- Level Explanatory Variables 
State- level variables were also extracted from a number of external data sources. Cervical 
cancer screening rates were extracted from the Behavioral Risk Factor Surveillance System 
(BRFSS).
62
 Research suggests that the most significant predictor of late stage CVC diagnosis is 
current screening, which is largely impacted by access to care. 
5, 17-19
 Thus, we control for this 
variable using BRFSS data at the state level to help explain the relationship between access to 
CVC screening and stage at CVC diagnosis. The percent of the state population insured by 
employers in private self-insured health plans in 2010 was obtained from the Agency for 
Healthcare Research and Quality (AHRQ).
43
 Individuals in private self-insured plans a 
population that accounts more than 50% of employees - were exempt from state mandates and 
many of the ACA provisions.
41
 These exclusions potentially undermine the potential for ACA 
and state mandates to have their intended effects. Although never before examined, we 
hypothesize that these loopholes significantly influence the number of women with access to 
CVC screening and thus are associated with later stage at diagnosis.   
Data describing state nurse practitioner regulations in 2012 and state cervical cancer screening 
mandates were extracted from the National Conference of State Legislatures.
63
 We categorized 
states into two groups: those that allowed NP autonomy to practice independently and/or 
prescribe medication as “autonomy” and states that did not allow NP autonomy to practice 
independently as “no autonomy.” From that, we created a binary indicator variable for each state 
specifying whether or not they allowed NPs autonomy to diagnose, treat, and prescribe without 
physician oversight. The influence of policy level variables on stage at CVC diagnosis is 
underexplored in the current literature. As described above, it is our hypothesis that the 
heterogeneity in these variables across states plays a huge role in access to CVC screening and 
pathways to late stage CVC diagnosis.  
 
 
Statistical Analysis 
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Descriptive statistics for the outcome and predictor variables were computed using SAS 
statistical software and are included in Table1. Two descriptive maps were also created to 
visualize the extent of the variation in proportion of late stage CVC diagnoses across counties 
and states (Figure of Maps 1-2). Mapping was done in QGIS software using standard deviation 
features that group rates by how many standard deviations (<2 sd : >2 sd) they are from the 
average county or national rate. This approach allowed us to visualize state- and county-level 
proportions of late stage CVC relative to the overall averages and provided evidence for the need 
to examine state and county predictors.   
To examine predictors of higher proportions of late stage CVC, we estimated a multilevel model 
using data from county- and state -levels. With counties nested within states, we specifically 
used General Linear Mixed Model (GLMM) to fit a two-level random intercept model, which 
allowed state intercepts to vary. Several county- and state-level covariates and one state-level 
interaction between percent of the state population in self-insured plans and CVC screening 
mandates were included in the model. Final random and fixed parameter estimates were 
calculated using Full Maximum Likelihood (FML) estimation in SAS 9.2 statistical software. We 
selected this model framework because it has been found to be the most efficient model for 
assessing correlated data or predictors at various levels simultaneously. Also, failing to adjust for 
existing multilevel effects is equivalent to having omitted variables in the model, which can bias 
standard errors and p-values for the estimated regression parameters.
49
   Ultimately, this model 
produces robust and reliable point estimates for study covariates. Together model estimation and 
mapping results helped to answer the following research questions: 
 
 Controlling for other variables, are counties with fewer federally funded health centers 
per 100,000 people associated with higher county-level proportions of late stage CVC? 
 Controlling for other variables, are counties with higher HPSA scores (greater need) 
associated with higher county-level proportions of late stage CVC? 
 Controlling for other variables, are states with higher private self-insured rates associated 
with higher county-level proportions of late stage CVC? 
 Controlling for other variables, are states with restrictive NP regulations associated with 
higher county- level proportions of late stage CVC? 
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 Controlling for other variables, are states without CVC screening mandates associated 
with higher county-level proportions of late stage CVC? 
 Does the effect of CVC screening mandates on the proportions of late stage CVC depend 
on state-level private self-insured rates? 
Results 
Descriptive Statistics 
During 2010-2014, the county-level average number of CVC cases among 2,357 counties is 25.  
Among these counties, the average percent of White women with CVC is 75.9%, Black women 
is 11.9%,  Hispanic women is 7.94%, American Indian women is 1.92%, Asian women is 1.35% 
and women of Other race or ethnicity is 1% . The sample also indicates that the average county-
level percent of women with CVC that were less than age 50 was approximately 48%. The CVC 
sample also shows that at the county-level an average of 55.56% of all CVC cases diagnosed 
during this period were late stage diagnoses. However, Figures 1-2 show that the proportion of 
late stage CVC varies tremendously across counties and states.  In regards to county-level 
variation, we found that in 379 counties the proportion of CVC cases diagnosed at a late stage 
was 1 standard deviation above the county- level average of 56% while the proportion of CVC 
cases diagnosed at a late stage CVC was 1 standard deviation below the county- level average in 
187 counties. Given the substantial variability in the proportion of CVC cases diagnosed at late 
stage across counties and states, it is our hypothesis that both county- and state- level factors 
contributed to late stage CVC incidence and geographic disparities. Table 1 provides the sample 
statistics for each of the county- and state- level study predictors. 
On average, the county-level percent of individuals that speak English poorly was approximately 
2%. We also found that there were more FQHCs than PPH clinics per capita, with approximately 
2.07 FQHCs per 100,000 people and less than 1 PPH clinic per 100,000 people in the US. In 
regard to HPSA score, there was a county-level average score of 8.21. In regards to poverty, we 
found that approximately 13% of counties were persistently poor for the past three decades. 
Finally, we found that there was an average of 310 people per square mile across counties, 
indicating that counties were more rural than urban. 
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At the state-level, approximately 60% of states had a CVC screening mandate and approximately 
56% of states did not allow NP autonomy to practice independently (i.e. no autonomy). We also 
found that the average percent of the state population insured by employers in private self-
insured plans and underserved by primary care providers were 59.47% and 11.59% respectively. 
Finally, we found that the state-level average rate for Pap screening in 2012 was 77.38%.  
Multilevel Model Results 
In Table 2, we provide the empirical results from multilevel modeling of ecological factors at the 
county- and state- levels with state-level factors as higher levels of influence. The column in 
Table 2 labeled “base model” reports effect estimates when no interaction term is included in the 
model. Examining base model results, we found that both counties with higher proportions of 
women with CVC under age 50 and counties with more PPH clinics per 100,000 people 
exhibited lower proportions of late-stage CVC than counties with lower levels of these variables. 
Specifically, model estimation shows that for every 1% increase in the county- level percent of 
women with CVC under age 50 there is a 0.26 of a percent decrease in the percent of late stage 
CVC across counties, controlling for all study predictors. At the county- level we also found that 
a 1 clinic increase in PPH clinics per 100,000 people is associated with a 0.02 point decrease in 
the proportion of late stage CVC across counties, controlling for all study predictors. On the 
other hand, the average county-level HPSA score was the only significant predictor positively 
associated with the proportion of late stage CVC across counties in the base model. At the 
county level, for every 1 point increase in the HPSA score there is a 0.002 point increase in the 
proportion of late stage CVC across counties, controlling for all study predictors.  
In the base model, no other county-level variables were found to be significantly associated with 
the average proportion of late stage CVC across counties. Although states varied widely in their 
regulations for NPs, CVC screening mandates and percent of the state population in self-insured 
plans, the base model also indicates that when controlling for all other study predictors none of 
these state- level variables are significantly associated with the average proportion of late stage 
CVC across counties. 
Table 2 also reports the effect estimates when the state-level interaction between CVC screening 
mandates and percent of the state population in self-insured plans are included. These estimates 
are under the column labeled “interaction.” In this model, we found that age less than 50, PPH 
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clinics per 100,000 people and HPSA score were still statistically significantly associated with 
the proportion of late stage CVC across counties. The interaction model estimates also tell us that 
the two policy variables (CVC screening mandates and percent of the state population in self-
insured plans) were statistically significantly associated with the county-level proportion of late 
stage CVC.  Finally, we found that there was a statistically significant interaction effect between 
CVC screening mandates and percent of the state population in self-insured plans. Understanding 
these effect estimates requires computing the marginal effects, which involves both terms – the 
main effects and the interaction effect.    
Model estimation suggests that the effect of the percent of the state population in self-insured 
plans on the county-level proportion of late stage diagnosis differs by whether or not the state has 
CVC screening mandates. Specifically, the marginal effects of the percent of the state population 
in self-insured plans on the proportions of late-stage CVC diagnosis in states with and without 
CVC screening mandates are as follows: 
dY/dXSELF = 0.00523 +(- 0.00469) (when mandate=1) = 0.00054 
dY/dXSELF = 0.00523 +(- 0.00469) (when mandate=0) = 0.00523 
These results imply that a positive relationship between the percent of the state population in 
self-insured plans and the proportions of late-stage diagnosis existed in states with and without 
CVC screening mandates.  However, this positive association was statistically significantly 
reduced in those states that had state CVC screening mandates. Specifically, higher proportions 
of the state population in self-insured plans were associated with lower county- level proportions 
of late-stage diagnosis in states with CVC mandates compared to states without CVC screening 
mandates.  
Goodness of fit statistics (AIC) suggest that both the base and interaction models have better 
model fits compared to the null model. However, AIC statistics indicate that the base model has 
a better model fit compared to the interaction model, 210 and 216.3 respectively. Although the 
interaction model has a larger AIC compared to the base model, there is a strong theoretical 
underpinning and evidence in the existing literature that suggests that there is a significant 
interaction between CVC screening mandates and self-insured rates. Thus, we believed the 
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interaction model was still a reasonable model to estimate and the results of this model are 
reliable. (Table 2)   
Discussion 
At the county-level we found that more than 55% of all CVC cases were diagnosed at a late stage 
during the time period 2010-2014. Study results also indicate that there is extreme variability in 
the proportion of late stage CVC across counties and states (Figures 1-2). This suggests that 
there are significant geographic disparities in late-stage CVC and that both factors at the county- 
and state- level may contribute to these disparities. Based on limitations in the existing literature, 
it was our hypothesis that these factors were mostly unexplored access to care barriers that varied 
across both geographic and socioecological levels. This study adds to the current body of 
literature by being the first to investigate and report findings on the multilevel access barriers 
influencing county-level proportions of late stage CVC and geographic disparities. This study is 
also the first to focus specifically on the relationship between late stage CVC and several state 
policies including: NP regulations, CVC screening mandates and the proportion of the state 
population in private self-insured plans.  
Among compositional factors, age less than 50 was the only factor statistically significantly 
associated with county-level proportion of late stage CVC.  Specifically, counties with higher 
proportions of women with CVC under age 50 were associated with lower proportions of late-
stage CVC. It is plausible that counties with higher proportions of women with CVC under age 
50 were associated with lower proportions of late-stage CVC because women of childbearing 
ages (i.e. <50 years) are more likely to have regular contact with reproductive healthcare 
providers and thus provided with more opportunities to adhere to CVC screening guidelines 
compared to women over 50. This highlights the need to increase the number of CVC screening 
programs and interventions that target women over age 50. More specifically, future intervention 
strategies could focus on changing the way women over 50 interact with the healthcare system, 
encouraging more regular primary healthcare visits. These visits would provide women over 50 
with more opportunities to adhere to CVC screening guidelines.   
While there was only one compositional factor associated with county-level proportions of late 
stage CVC, there were a number of contextual factors statistically significantly associated with 
109 
 
late stage CVC.  As expected, places with higher county- level HPSA scores (greater need) were 
statistically significantly associated with higher proportions of late stage CVC. The shortage of 
primary care physicians has been a well-known issue in the US for some time.
64 
This shortage 
was worsened by an aging population and an increased demand for physicians due to millions 
being newly insured under expanded insurance coverage provisions of the ACA beginning in 
2014.
65 
An existing shortage of PCPs and a newly developed need for physicians, creates an 
environment where there is poor access to healthcare services, including CVC screening. Thus, it 
was no surprise that counties that are high priority PCP shortage areas exhibited higher 
proportions of late stage CVC. This suggests that there is a need to find effective solutions to the 
growing need for primary care providers and emphasizes how important these solutions are for 
increasing access to those healthcare services that prevents adverse health outcomes such as late 
stage CVC.  
A number of solutions to the PCP shortage have been proposed, including expanding the role of 
NPs and having less restrictive NP regulations.
31-32,66
 Therefore, we expected that states with less 
restrictive NP regulations would have lower county-level proportions of late-stage CVC. 
Although model results show that states with less restrictive NP regulations were in fact 
associated with lower county-level proportions of late-stage CVC, this relationship was not 
statistically significant (Table 2).While less restrictive NP regulations may be a viable strategy 
for improving access to healthcare services
33
, it is plausible that the relationship between NP 
regulations and county-level proportions of late stage CVC depends on other factors not explored 
in the current study. For example, having less restrictive NP regulations is most important in 
rural areas where few supervising physicians are in close proximity and readily available to 
provide authorization via signatures. Thus, it is possible that a statistically significant 
relationship between NP regulations and county-level proportions of late stage CVC can only be 
observed when considering the interaction between NP regulations and urbanicity. Although our 
study controls for several factors including urbanicity, additional research is needed to determine 
what interactive and confounding effects impact the relationship between NP regulations and 
county-level proportions of late stage CVC. 
In addition to the PCP shortage being an access to care barrier influencing late stage CVC 
diagnosis, our results also suggest that fewer PPH clinics per 100,000 people was another access 
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barrier influencing stage at CVC diagnosis. Planned Parenthood clinics are publicly funded 
institutes that provide free or low cost reproductive and preventive services, including CVC 
screening, to individuals that are predominately racial and ethnic minority and low income.
67-69 
Given their service population, these results suggest that places with fewer PPH clinics per 
100,000 people are associated with geographical disparities in late stage CVC and plausibly 
socio-economic and racial disparities in stage at diagnosis. These results are of extreme 
relevance, as Planned Parenthood announced that they would voluntarily withdraw from Title X 
federal family funding programs, which provides PPH with nearly $60 million annually, rather 
than comply with new laws that forbids referrals to doctors who can perform abortions.
70
 Based 
on our results, it is our hypothesis that a significant lost in funding would restrict access to PPH 
clinics CVC screening services and thus impose a greater burden of late stage CVC in specific 
geographic areas. 
 
Overall our base model results suggest a number of county- level access barriers associated with 
higher proportions of late stage CVC, however, our interaction model results suggest that state- 
level policies also play a role in stage at CVC diagnosis. Specifically, we found that the two 
policy variables (CVC screening mandates and percent of the state population in self-insured 
plans) were statistically significantly associated with the county-level proportion of late stage 
CVC. We also found that there was a statistically significant interaction effect between CVC 
screening mandates and the percent of the state population in self-insured plans, indicating that 
the effect of one varies based on the level of the other. Neither of the two policy variables (CVC 
screening mandates and the percent of the state population in self-insured plans) were 
statistically significantly associated with late stage CVC in the base model. Therefore, interaction 
model results suggest that the associations between proportions of late stage CVC diagnosis and 
these two policies could not be discovered without controlling statistically for the effects of their 
interaction. This highlights the importance of considering these variables together when the aim 
is to determine their relationship with outcome variables, as our study shows that this approach 
can reduce confounding.  
When considering the interaction between CVC screening mandates and the percent of the state 
population in self-insured plans, the observed findings were as expected.   We found that states 
with higher proportions of the state population in self-insured plans were associated with higher 
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proportions of late stage CVC and this disparity was most pronounced when there was not a state 
CVC screening mandate. Although private self -insured plans are exempt from state mandates, 
state CVC screening mandates’ ability to lower the positive association between the percent of 
the state population in self-insured plans and proportions of late stage CVC could plausibly be 
explained by two underlying associations. First, it is plausible that some self -insured plans 
voluntarily covered CVC screening to avoid employee complaints. Second, it is also possible 
that some private self- insured employers in states with greater need of CVC screening (higher 
late-stage CVC rates) voluntarily covered CVC screening irrespective of being mandated to do 
so by state government, because it made good economic sense. Similar results were found in a 
2019 study examining the extent to which health plan expenditures for infertility services 
differed by whether coverage was provided by self-insured plan versus fully insured plans and by 
whether patients resided in states with or without mandates requiring coverage for infertility 
services.
71
 They found that there were higher infertility treatment expenditures for self-insured 
employers in states with mandates compared to states without mandates. 
71
   
In conclusion, study results suggest that there are significant geographic disparities in the late 
stage CVC diagnoses and that both factors at the county- and state- level contribute to these 
disparities. Specifically, there are significant county- and state- level access to care barriers 
influencing stage at CVC diagnosis. These barriers include primary care physician shortages, a 
lack of Planned Parenthood clinics and the absence of CVC screening mandates in states with 
higher proportions of the state population in self-insured plans. Addressing these barriers by way 
of policy change or targeted CVC interventions is essential to reducing the burden of late stage 
CVC in specific geographic areas. Based on our findings we recommend that cancer control 
interventions target counties with fewer PPH clinics per 100,000 people and counties with higher 
HPSA scores and proportions of women with CVC who are over the age of 50. Without doing 
such CVC mortality rates will remain high and at a disproportionately higher rate for women in 
some geographic areas.  
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Table 1: Descriptive Statistics 
County Data (n=2,357)  
Variable Name Mean or 
proportion 
Standard 
deviation 
Minimum and 
maximum values 
Late-stage CVC 
 
0.5556 0.2564 0,1 
Age < 50 
 
0.4792 0.2472 0,1 
American Indian 
 
0.0192 0.0977 0,1 
Asian  
 
0.0135 0.0513 0,1 
Non-Hispanic Black 
 
0.1190 0.2170 0,1 
Hispanic 
 
0.0794 0.1749 0,1 
Other 
 
0.0094 0.0543 0,1 
Non-Hispanic White 
 
0.7593 0.2809 0,1 
Proportion Speaking 
English poorly 
 
0.0193 0.0607 0, 0.8286 
Urbanicity =pop10/land 
 
310.4118 1971.6079 0, 69178.9916 
FQHCs per 100,000 people 
 
2.0748 4.8789 0,100.35 
PPH clinics per 100,000 
people 
 
0.2004 0.7267 0, 9.344 
Title X funded clinics per 
100,000 people 
 
3.8968 5.4676 0,63.271 
HPSA-score 
 
8.2126 5.1585 0,24 
 Persistent Poverty 
No 
Yes 
 
2035 (87.11%) 
301 (12.89%) 
 
NA, binary 
variable 
 
NA, binary 
variable 
State Data (n=43) 
 Pap Screening rate in 2012 
 
77.3813 3.1797 68.50,82.20 
% of the state population in 
self-insured plans 
 
59.4720 6.8522 46.70, 73.50 
Underserved by a PCP 
 
11.5977 6.9340 0.3252, 31.507 
Nurse Practitioner 
Regulations in 2012 
No Autonomy 
Autonomy  
 
 
 
19 (44.19%) 
24 (55.81% ) 
 
 
NA, binary 
variable 
 
 
NA, binary 
variable 
CVC screening mandate 
No 
Yes 
 
 
17 (39.53%) 
26 (60.47%) 
 
NA, binary 
variable 
 
NA, binary 
variable 
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Table 2: Ecological Model Results 
 Base Model Interaction  
Covariate Coefficient  Error p-value Coefficient  Error p-value 
County compositional  
variable  
Intercept 0.7696 0.2398 0.0027 0.5375 0.2564 0.043 
 
American Indian  
 
-0.05468 
 
0.05785 
 
0.3447 -0.0517 0.05761 0.3696 
 
Asian 
 
0.08512 
 
0.1118 
 
0.4465 0.07221 0.1118 0.5186 
 
Non-Hispanic Black 
 
0.02043 
 
0.03013 
 
0.4977 0.0189 0.02993 0.5278 
 
Hispanic 
 
0.02820 
 
0.04187 
 
0.5008 0.0246 0.04165 0.5549 
 
Other 
 
0.06428 
 
0.1171 
 
0.5830 0.06649 0.117 0.57 
 
Non-Hispanic White 
 
0 
 
- 
 
- 
 
0 
 
- 
 
- 
 
Age <50 
 
-0.2637 
 
0.02182 
 
<.0001 -0.2635 0.02182 <.0001 
County contextual  
Variable 
PPH clinics per 
100,000 people 
 
-0.02015 
 
0.008489 
 
0.0177 -0.01957 0.008454 0.0207 
 
FQHCs per 100,000 
people 
 
 
0.000659 
 
 
0.001146 
 
 
0.5653 0.0007 0.001145 0.5411 
 
TitleX funded clinics 
per 100,000 people 
 
 
0.000357 
 
 
0.001093 
 
 
0.7438 0.000442 0.00109 0.6853 
 
HPSA Score 
 
0.002255 
 
0.001122 
 
0.0446 0.002365 0.00112 0.0348 
 
Proportion Speaking 
English poorly 
 
 
0.05543 
 
 
0.1157 
 
 
0.6320 0.05575 0.1155 0.6293 
 
Urbanicity=pop10/land 
 
-1.49E-6 
 
2.733E-6 
 
0.5844 -1.63E-06 2.73E-06 0.5494 
 
Persistent Poverty 
Yes 
No (REF) 
 
 
0.01853 
0 
 
 
0.01818 
 
 
0.3083 
- 
0.019660 
0 
0.01813 
 
0.2784 
- 
State contextual  
Variable 
CVC Screening rate in 
2012 
 
 
-0.00296 
 
0.002836 
 
0.2965 
   
% of state population 
in Self Insured plans 
 
0.002052 
 
0.001201 
 
0.0875 0.005238 0.001913 0.0062 
 
Percent Underserved 
by a PCP 
% 
 
 
-0.00024 
 
 
0.001267 
 
 
0.8469 0.000047 0.001206 0.9686 
  
CVC screening 
 
 
 
 
 
 
 
 
 
 
 
 
-0.00262                 0.002677        0.3281 
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mandate 
Yes 
No (REF) 
 
 
0.004500 
0 
 
0.01712 
 
0.7927 
- 
 
0.2935 
0 
 
0.14 
 
 
0.0361 
Nurse Practitioner 
Regulations in 2012 
Autonomy (REF) 
No Autonomy  
 
 
 
-0.01866 
0 
 
 
0.01621 
 
 
0.2498 
- 
   
Xself13* State CVC 
Mandate 
 
- 
 
- 
 
- 
 
-0.00469 0.002259 0.0382 
Variance Components 
(state level) 
 
 
0.000934 
 
 
0.000540 
 
 
0.0419 0.00067 0.000502 
 
 
0.091 
Variance Components 
(county- level) 
 
 
0.05981 
 
 
0.001820 
 
 
<.0001 0.05984 0.001823 
 
 
<.0001 
Goodness of fit 
*AIC of null 278 
 
AIC=210 
 
AIC=216.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-0.010940 
0 
0.01553 
 
0.4811 
- 
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Chapter 5 
Summary of Background, Gaps in Literature and Specific Aims 
Approximately 51% of women with cervical cancer (CVC) are diagnosed at a late stage (regional 
or distant),
1
 an outcome associated with increased morbidity and mortality.
2 
African American,
3-4
 
Hispanic women,
3 
and women residing in specific geographic regions of the US are among those 
most heavily burdened by late stage CVC.
3 
Existing literature suggests that the most significant 
predictor of late stage CVC diagnosis and disparities is current screening (i.e. having a Pap 
smear within the past three years), which is largely impacted by access to care.
5-7
 Provisions 
under the ACA, including expanded insurance coverage options available to people with pre-
existing conditions beginning in 2010, mandated coverage of CVC screening without cost-
sharing beginning in 2012 and Medicaid expansion beginning in 2014, have helped to mitigate 
the issue of poor access to healthcare.
8-10
 However, limitations and loopholes that reduce the 
intended effects of the ACA suggest that access to care is still a significant contributor of late 
stage CVC and disparities.
10-13
 Thus, the overall goal of this three-part study was to identify 
access-related predictors of late stage CVC and develop a comprehensive understanding of 
where and why racial and geographic disparities in late stage CVC occur. 
While several studies have helped to advance our understanding of disparities in stage at CVC 
diagnosis and their relationship with access to care, the majority of the studies in the literature 
are either outdated, included a small sample of the US population, or presented notable 
limitations in their modeling approaches. To address these limitations and to fill gaps in the 
literature, we applied unexplored model-based constructs, novel spatial and multilevel 
methodologies and examined 43 states in the USCS cancer registry database, to carry out three 
specific aims, as follows: 
 Aim 1: Using spatial autocorrelation methods, we identified clusters of counties 
considered to be high risk for late stage CVC “hotspots” during two 5-year time periods 
(pre- and post-2010), determined whether hotspots were associated with various 
contextual and compositional factors and determined whether there were hotspots that 
persisted over both time periods.  
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 Aim 2: Using multilevel modeling methods, we examined the relationship between the 
odds of late stage CVC among women and various individual- and county - level 
predictors, with a primary focus on unexplored measures of the availability and 
affordability constructs of the Theory of Access described in Chapter 1. Under this aim 
we also determined whether the unexplored measures of the availability and affordability 
were associated with racial or ethnic disparities in late stage CVC. The primary predictive 
measures of interest were primary care physician shortage areas and the number of CHCs 
and other publicly funded clinics available per 100,000 people.  
 Aim 3: Using ecological multilevel modeling methods, we examined county-level 
disparities in late stage CVC across 43 states in the United States and explained the 
observed geographic disparities with numerous covariates.  We identified statistically 
significant ecological relationships between high proportions of late stage CVC diagnoses 
in counties and several county and state-level access to care predictors. Among the study 
predictors, we primarily focused on unexplored measures of the health policy construct 
outlined in the Access to Care Framework. The primary measures of interest included: 
state CVC screening mandates, percent of the population in self-insured plans and nurse 
practitioner regulations.  
 
Summary of Results & Implications 
Summary of Study 1 Results & Implications 
Under study Aim 1, we not only found that the overall proportion of late stage CVC diagnoses 
increased from 47% to 54%  over the two time periods, but that the distribution of late stage 
CVC across counties also changed over time. More specifically, we found that the distribution of 
“hotspot” clusters was different pre- and post- 2010 and that only a few hotspot clusters 
remained stationary over the two time periods. These results helped us to pinpoint geographical 
areas that were in greatest need of intervention during earlier times, more recent times and both 
time periods (i.e. worse places). Persistent late stage CVC hotspot clusters (i.e. worse places) 
were most apparent in California, Louisiana, Alabama and Georgia. Study Aim 1 results also 
helped us to determine whether the underlying factors associated with these hotspots changed 
over time. We found that demographic concentrations of Blacks were not associated with hotspot 
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clusters identified in the early period but were associated with hotspot clusters in the later period. 
Demographic concentrations of Hispanics were not associated with hotspot clusters identified 
during either time periods. We also found that the hotspot clusters identified in the later period 
were more strongly associated with access to care barriers than hotspot clusters identified in the 
earlier period. This suggests that over time access to care barriers likely became the primary 
drivers of late stage CVC diagnoses.  
Ultimately, hotspot clusters showed that there was extreme variability in the proportion of late 
stage CVC across counties and that clusters often contained counties in adjacent states. These 
results confirm that there were geographical disparities in late stage CVC, as demonstrated on 
maps of the analytic results.  Based on these results, we were also able to hypothesize that factors 
influencing late stage CVC likely exist at both the county and state level. By observing the 
change in the associations between hotspot clusters and various indicators of access to care over 
the two time periods, these results further helped us to generate reasonable hypotheses regarding 
which access to care barriers were and were not significantly mitigated by the ACA provisions 
implemented during 2010-2014. These results could inform future policies and research aiming 
to identify factors that potentially reduce the intended effects of the ACA.  Furthermore, the 
associations between various access to care variables and the hotspot clusters identified in the 
later period helped us to generate hypotheses regarding what types of access to care barriers (i.e. 
structural, health market or policy)  would be significant predictors of late stage CVC during 
2010-2014 if they were included in a multivariate, predictive statistical model.  
Summary of Study 2 Results & Implications 
Given the considerable variability in the proportion of late stage CVC across counties observed 
in the results under Aim 1, we hypothesized that significant county level factors were likely 
associated with stage at diagnosis among women. Thus, under study Aim 2, we assessed the 
relationships with access to care barriers occurring at the county level while accounting for some 
consistently identified individual level factors associated with late stage CVC.  To our 
knowledge, this study is unique. Consistent with previous literature, we found that Black and 
Hispanic women with CVC and women with CVC who were over the age of 50 exhibited greater 
odds of late-stage CVC compared to White women and women under age 50. This study’s 
unique contribution was several significant findings at the county level.  Results suggest that  the 
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percent of the population that had moved into the county from a different country in the year 
prior and the number of Planned Parenthood (PPH) clinics per 100,000 people were both 
negatively associated with a woman’s odds of late-stage CVC diagnosis. These findings suggest 
that as the value of these two county-level variables increased, the odds of late stage CVC among 
women with CVC decreased, on average. On the other hand, county-level percent of uninsured 
individuals and the percent of individuals in poverty were positively associated with a woman’s 
odds of late stage CVC diagnosis. Finally, we found that the relationship between the number of 
Planned Parenthood clinics per 100,000 people and stage at cervical cancer diagnosis differ by a 
woman’s race or ethnicity. Specifically, we found that a greater number of PPH clinics per 
100,000 people was associated with lower odds of late stage diagnosis among Hispanic women 
with CVC as compared to White women with CVC. 
The results from study Aim 2 ultimately highlight significant disparities in late stage CVC 
among racial or ethnic groups, the need to consider the influence of characteristics of place on 
individual health outcomes, and how important affordability of health care services is to health in 
the US. While the relationship between measures of availability of health care services and stage 
at diagnosis were insignificant, we found that several measures of affordability of health care 
were significantly associated with the odds of late stage CVC. Percent uninsured, percent in 
poverty and the number of PPH clinics (which provide services at low or no cost) all represent 
affordability of health care services and their relationship with stage at diagnosis among women 
suggests that future interventions should address cost and/or affordable coverage. Given that 
more PPH clinics is a protective factor for Hispanic women with CVC, future interventions 
should also focus on maintaining or increasing the number of publicly funded clinics to mitigate 
racial or ethnic disparities in health outcomes.  
Summary of Study 3 Results & Implications 
While we were interested in understanding what factors were associated with late stage diagnosis 
among women, we were also interested in understanding what factors were associated with the 
variability in late stage CVC among places (i.e., counties in the 43 states). Research using 
ecological modeling to explain geographic disparities in late stage CVC is less commonly done 
in the literature to date. Yet, this research can be essential for pinpointing those factors that either 
introduce benefits or barriers in specific places. Thus, under study Aim 3, we focused on 
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ecological relationships to identify significant factors associated with geographic disparities in 
late stage CVC.  We found that counties with greater needs for primary care physicians and 
larger proportions of older women with CVC were significantly associated with higher 
proportions of late stage CVC among counties. In regards to state policy levers, we found that 
state level nurse practitioner regulations were not significantly associated with the proportion of 
late stage CVC among counties. However, we did find that an unexplored and interactive 
relationship between CVC screening mandates and self-insured rates was significantly associated 
with the proportion of late stage CVC among counties. Specifically, we found that that states 
with higher proportions of the population in self-insured plans were associated with higher 
proportions of late stage CVC and this disparity was most pronounced when there was not a state 
CVC screening mandate.  
Self-insured plans account for more than 50% of persons with employer-sponsored health 
insurance.
14 
However, private employer self-funded plans are exempt from most state insurance 
laws, including mandated benefits.
15 
Thus, when studying the effects of these mandates by states, 
it is essential to consider how much of the self-insured population is in public or private plans yet 
before our study this had never been done. Although we expected a different relationship than 
what was observed, our significant results suggest that health policy plays an important role in 
the etiological pathway to late stage CVC diagnosis and should be further studied. For example, 
additional research should be carried out to determine what policies or health system changes are 
needed to mitigate the impact of primary care shortage areas or the effects of self-insured plans 
on the proportion of late stage CVC. 
Our results suggest that primary care physician (PCP) shortages are   associated with high 
proportions of late stage CVC.  Yet, whether or not NPs (which were introduced into the 
healthcare system, in part, as a solution to the PCP shortage) have autonomy to practice 
independently is not associated with county level proportions of late stage CVC. Thus, other 
policies or intersections of policies should be explored to determine effective approaches to 
eliminating the effects of PCP shortage areas on the county level proportion of late stage CVC.  
Ultimately, the results under study Aim 3 demonstrate how impactful county-level interventions 
and state-level policies can be to population health and suggest the need to focus on developing 
more multilevel interventions.  
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Limitations 
Although significant results were yielded, our three-part study demonstrated several study 
limitations. The most apparent study limitation was the use of an incomplete sample of the US 
population (n=43 states). Because seven states were excluded from each of the three studies, we 
were not able to generalize our study results to the entire US population. Carrying out LISA 
cluster analyses using data that excludes seven states imposes further limitations on Study 1 
results as the clustering of counties into distinct cluster groups (i.e. hotspots or coolspots) is 
based on whether or not a county is surrounded by neighboring counties with similar rates. 
Therefore, it is likely that the distribution of clusters across the US, during both the early and late 
period, would be different if the counties of the remaining seven states were included and 
assessed relative their neighboring counties.  
In addition to the exclusion of seven states, another study limitation was that we only included a 
short list of individual level predictors of late stage CVC. Although the literature indicates that 
marital status, education, income, insurance type and usual source of care are individual level 
predictors of late stage CVC, we did not have access to many of these variables and thus could 
not control for them in Study 2 multilevel model. Failure to account for these variables could 
likely bias study estimates. Finally, because late stage CVC is impacted by factors at the 
individual, county and state levels, it is possible that our study results may be limited by our use 
of a two rather than three-level model. Although there are several challenges associated with 
estimating and interpreting three-level models, we acknowledge that it is important to account 
for the true hierarchal suture of the data to more accurately model reality and derive unbiased 
estimates.  
Future Research 
Although the current studies yield insightful results, there are still several aspects of the 
etiological pathway to late stage CVC and disparities that are not well understood. As previously 
mentioned, study results suggest that PCP shortage areas are associated with stage at CVC 
diagnosis, yet less restrictive NP regulations which could increase the availability of providers 
offering primary care services are not associated with stage at diagnosis. Thus, additional 
research is needed to determine whether the relationship between NP regulations and stage at 
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CVC is dependent upon unexplored and interactive relationships with factors such as urbanicity 
or whether other factors that address the issue of PCP shortage areas are more effective in 
reducing the odds of late stage CVC. For example, tuition reimbursement incentives for students 
willing to serve in PCP shortage areas are alternative approaches to the PCP shortage and thus 
could be more effective in reducing the odds of late stage CVC compared to less restrictive NP 
regulations. Ultimately, there is a need to understand how to address PCP shortage areas so that 
it does not continue to serve as a barrier to CVC screening.  
Additional research is also needed to more thoroughly understand the relationship between 
health policy changes implemented as a result of the Affordable Care Act and late stage CVC 
diagnoses and disparities. The current study included data from 2010-2014, which were the most 
recently available data during the onset of our study. While several provisions of the ACA were 
implemented during this time period, there are often delays in the effects of health policies. Thus, 
the effects of access to care barriers are expected to diminish over time, and carrying out the 
same studies using more current data would likely provide additional insights regarding the 
effects of the ACA on access to CVC screening and stage at CVC diagnosis. Further, based on 
the significant role self-insured plans played in stage at CVC diagnosis during 2010-2014, 
additional research is also needed to determine whether or how the role of self-insured 
enrollment rates in states changes during a later time period. Self-insured plans are exempt from 
state mandates and regulations, but not exempt from federal laws, such as provisions under the 
ACA, except through grandfathered plans, not subject to the new provisions, for a limited time 
period.  Thus, research is needed to determine whether, as the number of grandfathered plans 
dwindles, high numbers of self-insured rates continue to reduce the intended effects of the ACA 
on access to CVC screening and, thus, stage at diagnosis.  
In addition to carrying out similar studies using more current data, research is needed to 
understand those factors associated with disproportionately higher rates of late stage CVC among 
Hispanic and African American women and women over the age of 50. Although study findings 
suggest that the availability of PPH clinics plays a role in stage at diagnosis among Hispanic 
women, PPH clinic availability does not explain 100% of the observed differences in late stage 
CVC rates among Hispanic and White women. However, these findings do suggest that other 
unexplored indicators of access to care could play a significant role in these disparities. Thus, 
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future research should focus on identifying those access to care barriers associated with racial 
and age-based disparities in late stage CVC.  
Although additional research is needed to understand racial, ethnic and age disparities in stage at 
CVC diagnoses, health disparities overall have been found to vary from place to place and race 
or ethnic disparities and geographic disparities are often confounded.
16-18
 Specifically, 
confounding interactions between race and place have been found to bias national estimates such 
that they suggest that racial dipartites exist when in actuality whole regions with higher 
concentrations of minorities have worse outcomes.
19
 Consequently, conclusions and implications 
drawn at the national level may not reflect what each individual state may be experiencing or 
most benefited by. Thus, future research should aim to disentangle the effects of place from 
socio-demographic determinants of health and determine in what states access to care barriers 
such as publicly funded health center density and PCP shortage is associated with racial or ethnic 
disparities in late stage CVC diagnosis. These results could be used to present state-level 
officials with information concerning whether or not racial disparities in late stage CVC exists in 
their states and to encourage state based action and interventions to reduce late stage CVC 
diagnosis rates and disparities. 
Finally, given that these significant access barriers occurred at various ecological and 
geographical levels, we recommend that future research and intervention efforts begin to focus 
more on multilevel and/or spatial approaches. Prior to our studies, neither advanced spatial 
analytic methods nor multilevel modeling had been applied in studies aiming to identify 
geographic areas in greater need of intervention and factors underlying racial or geographical 
disparities in stage at CVC diagnosis. Yet, these advanced methods have proven useful for public 
health surveillance and understanding disease etiology and disparities among an array of other 
health outcomes.  
The current study applied such innovative multilevel model methods to estimate both an 
individual and county level model as well as a county and state level model. However, much 
could be gained from examining the simultaneous effects of factors occurring at not only two 
levels but at three levels. For example, estimating a three level model that accounts for factors 
occurring at the individual, county and state level together would more accurately reflect reality 
and thus allow researchers to derive a more comprehensive understanding of those barriers 
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impacting stage at CVC diagnosis. Ultimately, using more innovative research methods and 
intervention strategies could allow researchers to better understand and combat the issue of late 
stage CVC in the US.  
Take Home Message  
Overall, the results from these studies demonstrate that there are significant demographic and 
geographic disparities in late stage CVC, and that access to CVC screening plays a significant 
role in the etiological pathway to late stage diagnoses and disparities. We found that primary care 
physician shortage areas, the number of Planned Parenthood clinics per 100,000 people, area-
level poverty rates, area-level uninsured rates, percent of the population that moved from a 
different country, state CVC screening mandates and proportion of the state population in self-
insured employer health plans were statistically significant predictors of access to care associated 
with late stage CVC diagnoses and geographic disparities. We also found that Planned 
Parenthood clinics play an important role in reducing the odds of late stage CVC among 
Hispanic women with CVC. However, additional research is needed to understand those factors 
associated with higher odds of late stage CVC among African American women. Given that 
these significant access barriers occurred at various ecological and geographical levels, we 
recommend that future research and intervention efforts begin to focus more on multilevel and/or 
spatial approaches. With 51% of cervical cancer cases diagnosed at a late stage
1
 it is important to 
utilize more innovative methods for identifying the factors associated with late stage cervical 
cancer diagnosis and disparities. Without doing such CVC mortality rates will remain high and at 
a disproportionately higher rate for women in various geographical areas and among African 
American and Hispanic women.
20-22
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